

# CITATION REPORT

List of articles citing

## EASL Clinical Practice Guidelines: management of cholestatic liver diseases

DOI: 10.1016/j.jhep.2009.04.009  
Journal of Hepatology, 2009, 51, 237-67.

**Source:** <https://exaly.com/paper-pdf/46754547/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1424	Diagnostik bei erhöhten Leberwerten. <b>2009</b> , 4, 557-572		3
1423	Primary biliary cirrhosis. <b>2009</b> , 31, 283-307		129
1422	Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1084-5; author reply 1085-6	13.4	12
1421	Oral antiviral therapies are cost-effective vs. no treatment but indirect comparisons should be avoided. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1086-7; author reply 1087-8	13.4	1
1420	Ursodeoxycholic acid in primary biliary cirrhosis: Reply. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 1085-1086	13.4	26
1419	Foie et grossesse. <b>2010</b> , 5, 1-11		
1418	Cirrhose biliaire primitive. <b>2010</b> , 5, 1-7		0
1417	Cirrhose biliaire primitive. <b>2010</b> , 5, 1-4		
1416	Hépatopathies gravidiques. <b>2010</b> , 5, 1-8		
1415	Current world literature. <b>2010</b> , 26, 286-97		
1414	Cystic fibrosis-associated liver disease. <b>2010</b> , 24, 585-92		67
1413	Differenzialdiagnose Ikterus. <b>2010</b> , 5, 363-372		0
1412	Postgraduate Course: Integrating Basic Science into Clinical Practice. <b>2010</b> , 4, 1-85		78
1411	Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis. <b>2010</b> , 12, 13-22		19
1410	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. <b>2010</b> , 126, 228-43		70
1409	The predictors of the presence of varices in patients with primary sclerosing cholangitis. <b>2010</b> , 51, 1302-10		18
1408	Biliary physiology and disease: reflections of a physician-scientist. <b>2010</b> , 51, 1095-106		19

1407	The biliary HCO <sub>3</sub> <sup>(-)</sup> umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. <b>2010</b> , 52, 1489-96	222
1406	The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. <b>2010</b> , 52, 1334-40	71
1405	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauroolithocholic acid-induced cholestasis in rat liver. <b>2010</b> , 52, 1758-68	32
1404	Primary sclerosing cholangitis. <b>2010</b> , 24, 655-66	44
1403	Hereditary liver diseases. Preface. <b>2010</b> , 24, 529	1
1402	Learning from the pregnane X receptor: how to fight one aggressor with two strategies. <b>2010</b> , 30, 161-3	1
1401	Pharmacotherapy of cholestatic liver diseases. <b>2010</b> , 11, 119-25	16
1400	11 Erkrankungen der Mutter in der Schwangerschaft/schwangerschaftsinduzierte Erkrankungen (XIX). <b>2010</b> ,	
1399	[ALT screening for chronic liver diseases: scrutinizing the evidence]. <b>2010</b> , 48, 46-55	36
1398	Treatment options for primary sclerosing cholangitis. <b>2010</b> , 4, 473-88	16
1397	Advances in hepatobiliary pathology: update for 2010. <b>2010</b> , 14, 747-62	3
1396	Clinical implications of novel aspects of biliary pathophysiology. <b>2010</b> , 42, 238-44	14
1395	Update on primary sclerosing cholangitis. <b>2010</b> , 42, 390-400	81
1394	Update on primary biliary cirrhosis. <b>2010</b> , 42, 401-8	54
1393	Bile salts and cholestasis. <b>2010</b> , 42, 409-18	115
1392	Current topics in autoimmune hepatitis. <b>2010</b> , 42, 757-64	18
1391	Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. <b>2010</b> , 42, 911-2	16
1390	Lysophosphatidic acid is a potential mediator of cholestatic pruritus. <b>2010</b> , 139, 1008-18, 1018.e1	271

1389	Pathogenesis of cholestatic liver disease and therapeutic approaches. <b>2010</b> , 139, 1481-96		179
1388	Liver disease associated with canalicular transport defects: current and future therapies. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 258-71	13.4	126
1387	Primary biliary cirrhosis: a 2010 update. <i>Journal of Hepatology</i> , <b>2010</b> , 52, 745-58	13.4	218
1386	Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 307-12	13.4	86
1385	MARS: The ultimate warrior against pruritus of cholestasis?. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 228-9	13.4	2
1384	Geoepidemiology of autoimmune liver diseases. <b>2010</b> , 34, J300-6		69
1383	PBC screen: an IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. <b>2010</b> , 35, 436-42		103
1382	[Pruritus associated with cholestasis]. <b>2010</b> , 33, 313-22		0
1381	ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene. <b>2010</b> , 40, 937-41		26
1380	Cirrosis biliar primaria. <b>2010</b> , 14, 1-4		
1379	Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. <b>2010</b> , 8, 530-4		79
1378	Primary sclerosing cholangitis: overview and update. <b>2010</b> , 7, 611-9		42
1377	The Liver in Pregnancy. <b>2011</b> , 271-293		0
1376	Cirrosi biliare primitiva. <b>2011</b> , 13, 1-4		
1375	The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. <b>2011</b> , 35, 29-33		15
1374	Cholestatic liver diseases: Are liver transplant criteria different?. <b>2011</b> , 5, 61-65		
1373	Pathophysiology and current management of pruritus in liver disease. <b>2011</b> , 35, 89-97		65
1372	Liver transplantation in PBC and PSC: indications and disease recurrence. <b>2011</b> , 35, 446-54		55

1371	Current consensus on the management of primary sclerosing cholangitis. <b>2011</b> , 35, 786-91		16
1370	Primary sclerosing cholangitis is changing clinical spectrum and old biomarkers disclose an innovative role: the case of alkaline phosphatase. <b>2011</b> , 43, 268-9		1
1369	Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. <b>2011</b> , 43, 887-92		37
1368	Vaccination for hepatitis C virus: closing in on an evasive target. <b>2011</b> , 10, 659-72		86
1367	Disease-specific autoantibodies in primary biliary cirrhosis. <b>2011</b> , 412, 502-12		73
1366	Primary sclerosing cholangitis and malignancy. <b>2011</b> , 25, 753-64		59
1365	Medical and endoscopic therapy of primary sclerosing cholangitis. <b>2011</b> , 25, 741-52		16
1364	Diagnosis of primary biliary cirrhosis. <b>2011</b> , 25, 701-12		28
1363	Pathogenesis of primary sclerosing cholangitis. <b>2011</b> , 25, 727-39		77
1362	Evolving concepts in primary sclerosing cholangitis. <b>2012</b> , 32, 352-69		20
1361	Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. <i>Journal of Hepatology</i> , <b>2011</b> , 54, 374-85	13.4	356
1360	Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1361-7	13.4	268
1359	A major step towards effective treatment evaluation in primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1178-80	13.4	11
1358	Hepatopatías gravídicas. <b>2011</b> , 15, 1-7		
1357	Primary biliary cirrhosis. <b>2011</b> , 377, 1600-9		220
1356	Bezafibrate for primary biliary cirrhosis. <b>2011</b> ,		
1355	Clinical Variants of Primary Sclerosing Cholangitis: When Does Liver Biopsy Make the Diagnosis?. <b>2011</b> ,		
1354	The pharmacological management of intrahepatic cholestasis of pregnancy. <b>2011</b> , 6, 12-7		56

1353	The canalicular bile salt export pump BSEP (ABCB11) as a potential therapeutic target. <b>2011</b> , 12, 661-70	23
1352	Mediators of pruritus during cholestasis. <b>2011</b> , 27, 289-93	16
1351	Neonatal ichthyosis and sclerosing cholangitis syndrome: extremely variable liver disease severity from claudin-1 deficiency. <b>2011</b> , 53, 350-4	32
1350	Cholangites sclerosantes. <b>2011</b> , 6, 1-10	1
1349	Bisphosphonates for osteoporosis in primary biliary cirrhosis. <b>2011</b> ,	0
1348	Jaundice and Cholestasis. <b>2011</b> , 234-256	2
1347	Primary Biliary Cirrhosis. <b>2011</b> , 329-341	
1346	Hormone replacement for osteoporosis in women with primary biliary cirrhosis. <b>2011</b> , CD009146	7
1345	Hormone replacement for osteoporosis in women with primary biliary cirrhosis. <b>2011</b> ,	0
1344	Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. <b>2011</b> , 33, 1273-91	36
1343	Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. <b>2011</b> , 34, 497-508	78
1342	Extracorporeal artificial liver support systems in the management of intractable cholestatic pruritus. <b>2011</b> , 31 Suppl 3, 31-3	7
1341	How to investigate asymptomatic abnormal liver function tests. <b>2011</b> , 39, 529-531	
1340	Primary sclerosing cholangitis. <b>2011</b> , 39, 588-591	2
1339	Complications of cholestasis. <b>2011</b> , 39, 605-606	
1338	Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats. <b>2011</b> , 43, 270-7	4
1337	Prognostic factors and survival analysis of antimitochondrial antibody-positive primary biliary cirrhosis in Chinese patients. <b>2011</b> , 56, 2750-7	10
1336	[Treatment of autoimmune liver diseases. Autoimmune hepatitis and primary sclerosing cholangitis]. <b>2011</b> , 52, 1394-406	2

1335	The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. <b>2011</b> , 11, 83	64
1334	Autoimmune liver disease - are there spectra that we do not know?. <b>2011</b> , 10, 9	7
1333	Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. <b>2011</b> , 8, 72	47
1332	Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. <b>2011</b> , 17, 1137-51	54
1331	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <b>2011</b> , 53, 2121-9	67
1330	Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. <b>2011</b> , 54, E1-9	52
1329	Cancer surveillance in patients with primary sclerosing cholangitis. <b>2011</b> , 54, 1842-52	204
1328	Hepatitis B reactivation in patients with inflammatory bowel disease: A prospective survey on screening and prevention practices at general hospitals in France. <b>2011</b> , 17, 669-70	3
1327	Update on the epidemiology of primary biliary cirrhosis. <b>2011</b> , 5, 583-90	4
1326	Adult jaundice—the pathophysiology, classification and causes. <b>2011</b> , 9, 34-40	4
1325	Dissecting the genetic heterogeneity of gallbladder stone formation. <b>2011</b> , 31, 157-72	46
1324	'It's as if PBC didn't exist': the illness experience of women affected by primary biliary cirrhosis. <b>2011</b> , 26, 1429-45	14
1323	Deciphering the genetic predisposition to primary sclerosing cholangitis. <b>2011</b> , 31, 188-207	21
1322	Bisphosphonates for osteoporosis in primary biliary cirrhosis. <b>2011</b> , CD009144	16
1321	[Primary sclerosing cholangitis - challenges for all. The German Study Group PSC]. <b>2011</b> , 49, 63-5	
1320	Differenzialdiagnose der Cholestase. <b>2011</b> , 7, 87-101	
1319	Primary biliary cirrhosis associated with systemic sclerosis: diagnostic and clinical challenges. <b>2011</b> , 2011, 976427	32
1318	Pregnancy in primary sclerosing cholangitis. <b>2011</b> , 60, 1117-21	47

1317	Primary sclerosing cholangitis: diagnostic and therapeutic problems. <b>2011</b> , 29 Suppl 1, 41-5	15
1316	Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. <b>2011</b> , 29, 117-8	6
1315	Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis. <b>2011</b> , 38, 2180-5	26
1314	Primary sclerosing cholangitis. <b>2011</b> , 185, 117-33	10
1313	Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. <b>2012</b> , 44, 934-9	22
1312	Vitamin d receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. <b>2012</b> , 2012, 408723	20
1311	The biliary HCO <sub>3</sub> <sup>(-)</sup> umbrella: experimental evidence revisited. <b>2012</b> , 28, 253-7	44
1310	The spectrum of sclerosing cholangitis and the relevance of IgG4 elevations in routine practice. <b>2012</b> , 107, 56-63	45
1309	Abstracts of the 43rd Nordic Gastroenterology Congress. June 12-15, 2012. Reykjavik, Iceland. <b>2012</b> , 47 Suppl 1, S14-84	1
1308	Health-related quality of life in chinese patients with chronic liver disease. <b>2012</b> , 2012, 516140	17
1307	TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis. <b>2012</b> , 2012, 487521	7
1306	Clinical Guideline of Primary Biliary Cirrhosis 2012 The Intractable Hepato-Biliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. <b>2012</b> , 53, 633-686	6
1305	Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience. <b>2012</b> , 24, 1051-8	129
1304	Long-chain PUFA in granulocytes, mononuclear cells, and RBC in patients with cystic fibrosis: relation to liver disease. <b>2012</b> , 55, 76-81	3
1303	Molecular targets for the treatment of fibrosing cholangiopathies. <b>2012</b> , 92, 381-7	10
1302	Manifestations hépatiques et biliaires des maladies inflammatoires chroniques des intestins. <b>2012</b> , 7, 1-8	
1301	Cholangite sclérosante primitive. <b>2012</b> , 7, 1-6	
1300	[Current trends in liver biopsy indications in chronic liver diseases]. <b>2012</b> , 41, 1064-70	4



1299	Sklerosierende Cholangitiden. <b>2012</b> , 7, 483-492		8
1298	Towards systemic sclerosis and away from primary biliary cirrhosis: the case of PTPN22. <b>2012</b> , 3, 1-9		7
1297	Popular and unpopular infectious agents linked to primary biliary cirrhosis. <b>2012</b> , 3, 95-104		3
1296	Pruritus in chronic cholestatic liver disease. <b>2012</b> , 16, 331-46		42
1295	[Autoimmune liver diseases]. <b>2012</b> , 53, 943-54; quiz 955-6		
1294	European guideline on chronic pruritus. <b>2012</b> , 92, 563-81		137
1293	<i>Helicobacter pylori</i> in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. <b>2012</b> , 14, 177-84		50
1292	Brushing of bile duct stenoses for the true dignity. <b>2012</b> , 32, 698-700		2
1291	[Management of obstetric cholestasis in France: A national survey of obstetrical practice]. <b>2012</b> , 41, 182-93		4
1290	Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 133-40	13.4	78
1289	Reply to IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 475	13.4	
1288	Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 637-41	13.4	36
1287	Primary biliary cirrhosis and Sjögren's syndrome: autoimmune epithelitis. <b>2012</b> , 39, 34-42		92
1286	Tauro-βmuricholic acid restricts bile acid-induced hepatocellular apoptosis by preserving the mitochondrial membrane potential. <b>2012</b> , 424, 758-64		27
1285	Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. <b>2012</b> , 56, 1391-400		174
1284	Pathogenesis of cholestatic itch: old questions, new answers, and future opportunities. <b>2012</b> , 56, 1194-6		11
1283	Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature. <b>2012</b> , 12, 92		23
1282	Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature. <b>2012</b> , 7, 100		5

1281	Evaluation of elevated liver enzymes. <b>2012</b> , 16, 183-98	36
1280	[S2k guideline--Chronic Pruritus]. <b>2012</b> , 10 Suppl 4, S1-27	29
1279	Ursodeoxycholic acid for primary biliary cirrhosis. <b>2012</b> , 12, CD000551	46
1278	Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. <b>2012</b> , 143, 1492-501	186
1277	PSC, AIH and overlap syndrome in inflammatory bowel disease. <b>2012</b> , 36, 420-36	41
1276	The bile salt export pump (BSEP) in health and disease. <b>2012</b> , 36, 536-53	120
1275	Primary biliary cirrhosis in Southern Israel: a 20 year follow up study. <b>2012</b> , 23, e193-8	17
1274	Doen hepica autoimune na crian e no adolescente - dificuldades no diagntico. <b>2012</b> , 19, 229-240	1
1273	Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. <b>2012</b> , 30 Suppl 1, 39-47	24
1272	The SLC10 carrier family: transport functions and molecular structure. <b>2012</b> , 70, 105-68	87
1271	Current pharmacotherapy for cholestatic liver disease. <b>2012</b> , 13, 2473-84	20
1270	Autoimmune Hepatitis. <b>2012</b> ,	2
1269	Primary sclerosing cholangitis and bile acids. <b>2012</b> , 36 Suppl 1, S21-5	6
1268	Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. <b>2012</b> , 86, 244-9	5
1267	Primary biliary cirrhosis and bile acids. <b>2012</b> , 36 Suppl 1, S13-20	20
1266	Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. <b>2012</b> , 61, 1657-69	551
1265	Bezafibrate for primary biliary cirrhosis. <b>2012</b> , 1, CD009145	11
1264	S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. <b>2012</b> , 7, e29821	21

1263	Epstein-barr virus as a trigger of autoimmune liver diseases. <b>2012</b> , 2012, 987471	30
1262	Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters. <b>2012</b> , 11, 710-714	14
1261	Current Trends in Liver Biopsy Indications for Chronic Liver Diseases. <b>2012</b> ,	2
1260	Acute liver failure in an antimitochondrial antibody-positive 63-year-old man. <b>2012</b> , 6, 394-9	1
1259	Primary sclerosing cholangitis. <b>2012</b> , 10, 8-8	
1258	9 Autoimmune liver disease.	
1257	Management of primary sclerosing cholangitis: conventions and controversies. <b>2012</b> , 26, 261-8	10
1256	Ursodeoxycholic acid in liver diseases. <b>2012</b> , 3, 138-142	
1255	Canalicular ABC transporters and liver disease. <b>2012</b> , 226, 300-15	89
1254	Gallbladder polyps in primary sclerosing cholangitis: indication for early intervention. <b>2012</b> , 56, 396; author reply 396	2
1253	Gallbladder polyps in primary sclerosing cholangitis: Indication for early intervention. <b>2012</b> , 56, 396-396	8
1252	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <b>2012</b> , 56, 198-208	208
1251	[Cholestatic pruritus : new insights into pathophysiology and current treatment]. <b>2012</b> , 63, 532-8	4
1250	Cutting-edge issues in primary biliary cirrhosis. <b>2012</b> , 42, 342-54	14
1249	Autoimmunity and environment: am I at risk?. <b>2012</b> , 42, 199-212	52
1248	Mesenteric panniculitis presenting as liver dysfunction. <b>2012</b> , 5, 113-8	5
1247	Malignancies and mortality in 200 patients with primary sclerosing cholangitis: a long-term single-centre study. <b>2012</b> , 32, 214-22	67
1246	Colorectal neoplasia in PSC-IBD patients: are times changing?. <b>2012</b> , 32, 175-6	1

1245	Antimitochondrial antibody -M2 positive autoimmune hepatitis during standard of care for chronic hepatitis C. <b>2012</b> , 42, 428-32	3
1244	Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. <b>2012</b> , 42, 1016-23	11
1243	Review article: overlap syndromes and autoimmune liver disease. <b>2012</b> , 36, 517-33	89
1242	Primary sclerosing cholangitis: diagnosis, prognosis, and management. <b>2013</b> , 11, 898-907	78
1241	Review article: the management of autoimmune hepatitis beyond consensus guidelines. <b>2013</b> , 38, 343-64	45
1240	Primary Sclerosing Cholangitis: Current and Future Management Strategies. <b>2013</b> , 12, 28-36	6
1239	Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. <b>2013</b> , 145, 521-36	290
1238	Systemic sclerosis at the crossroad of polyautoimmunity. <b>2013</b> , 12, 1052-7	47
1237	Liver transplantation and autoimmune liver diseases. <b>2013</b> , 19, 1065-77	64
1236	Update on primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 571-82	13.4 92
1235	Hepatobiliary quiz-6 (2013). <b>2013</b> , 3, 171-6	
1234	Primary Sclerosing Cholangitis with Dilatation of a Dominant Stenosis. <b>2013</b> , 1, 526-527	
1233	[Severe cholestatic hepatitis revealing a DRESS syndrome]. <b>2013</b> , 34, 645-8	3
1232	Intrahepatic cholestasis of pregnancy: a further important step in dissecting its genetic architecture. <b>2013</b> , 45, 266-7	5
1231	Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 1201-8	13.4 72
1230	Liver abnormalities in bowel diseases. <b>2013</b> , 27, 531-42	25
1229	Liver disease and malnutrition. <b>2013</b> , 27, 619-29	38
1228	Primary sclerosing cholangitis. <b>2013</b> , 382, 1587-99	370

1227	Antimitochondrial antibodies may be insufficiently specific to define primary biliary cirrhosis-like disease in mouse models. <b>2013</b> , 58, 828-30	6
1226	Clinical manifestations and treatment of drug-induced hepatotoxicity. <b>2013</b> , 17, 565-73, viii	11
1225	Overlap syndromes of autoimmune hepatitis: an open question. <b>2013</b> , 58, 344-8	9
1224	Primary biliary cirrhosis: is there still a place for histological evaluation?. <b>2013</b> , 37, 556-8	4
1223	Autoimmune hepatitis-primary biliary cirrhosis overlap syndrome concomitant with immune hemolytic anemia and immune thrombocytopenic purpura (Evans syndrome). <b>2013</b> , 37, e45-50	10
1222	Does an isolated benign choledochal stricture hide a PSC?. <b>2013</b> , 48, 1006-11	
1221	Hépatites auto-immunes de l'adulte. Expérience d'un service de médecine interne algérien. <b>2013</b> , 7, 220-224	
1220	Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. <b>2013</b> , 58, 1084-93	86
1219	Health-related quality of life and survival in Chinese patients with chronic liver disease. <b>2013</b> , 11, 131	19
1218	Role of endoscopy in primary sclerosing cholangitis. <b>2013</b> , 15, 361	4
1217	Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. <b>2013</b> , 37, 572-85	42
1216	Antineutrophil cytoplasmic antibodies in bile are associated with disease activity in primary sclerosing cholangitis. <b>2013</b> , 48, 1205-12	7
1215	Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. <b>2013</b> , 38, 794-803	11
1214	Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. <b>2013</b> , 38, 1354-64	25
1213	Intrahepatic cholestasis in common chronic liver diseases. <b>2013</b> , 43, 1069-83	38
1212	Recent advances in the morphological and functional heterogeneity of the biliary epithelium. <b>2013</b> , 238, 549-65	52
1211	Autoimmune hepatitis: a comprehensive review. <b>2013</b> , 41, 126-39	141
1210	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 750-6	13.4 21

1209	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 155-68	13.4	257
1208	Primary sclerosing cholangitis. <b>2013</b> , 17, 211-27		4
1207	Advances in pathogenesis and treatment of pruritus. <b>2013</b> , 17, 319-29		19
1206	The limitations and hidden gems of the epidemiology of primary biliary cirrhosis. <b>2013</b> , 46, 81-7		52
1205	Improvement of serum alkaline phosphatase to . <i>Journal of Hepatology</i> , <b>2013</b> , 58, 329-34	13.4	132
1204	A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 327-35	13.4	28
1203	Autoantibodies in primary biliary cirrhosis: antimitochondrial autoantibodies. <b>2013</b> , 37, 431-3		8
1202	The resurgence of serum alkaline phosphatase as a surrogate biomarker for prognosis in primary sclerosing cholangitis. <b>2013</b> , 11, 847-9		3
1201	FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 1278-84	13.4	59
1200	Liver transplant for cholestatic liver diseases. <b>2013</b> , 17, 345-59		16
1199	α integrin is a long-sought sensor for tauroursodeoxycholic acid. <b>2013</b> , 57, 867-9		8
1198	Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. <b>2013</b> , 7, 556-85		438
1197	Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. <b>2013</b> , 7, 253-61		29
1196	Primary sclerosing cholangitis: a review and update on therapeutic developments. <b>2013</b> , 7, 103-14		46
1195	Cholestatic liver disease overlap syndromes. <b>2013</b> , 17, 243-53		7
1194	Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B. <b>2013</b> , 41, 371-8		4
1193	Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. <b>2013</b> , 58, 1385-91		127
1192	Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. <b>2013</b> , 58, 273-83		115

1191	Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. <b>2013</b> , 57, 2390-8	91
1190	Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma. <b>2013</b> , 45, 612-5	8
1189	A case of primary biliary cirrhosis and autoimmune hepatitis overlap showing acute presentation and transient seropositivity for immunoglobulin G and anti-nuclear antibody. <b>2013</b> , 6, 465-9	
1188	Glucocorticoid receptor-dependent immunomodulatory effect of ursodeoxycholic acid on liver lymphocytes in mice. <b>2013</b> , 305, G427-38	19
1187	Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. <b>2013</b> , 11, 841-6	114
1186	Cholestatic liver disease. <b>2013</b> , 31, 152-4	27
1185	[Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]. <b>2013</b> , 51, 450-7	1
1184	Cholestatischer Pruritus: eine retrospektive Analyse klinischer Charakteristika und des Therapieansprechens. <b>2013</b> , 11, 158-169	2
1183	Hepatologische Erkrankungen in der Schwangerschaft. <b>2013</b> , 09, 25-40	2
1182	Reply to Ustundag et al. <b>2013</b> , 45, 228	
1181	The utility of duodenal endosonography examination in the diagnostic work-up of primary sclerosing cholangitis. <b>2013</b> , 45, 227	1
1180	Differenzialdiagnostisches Vorgehen bei Lebererkrankungen. <b>2013</b> , 09, 111-126	
1179	Combination therapy of ursodeoxycholic Acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. <b>2013</b> , 2013, 490731	20
1178	Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease. <b>2013</b> , 2013, 148526	19
1177	Treatment of autoimmune liver disease: current and future therapeutic options. <b>2013</b> , 4, 119-41	34
1176	Production of apolipoprotein C-III knockout rabbits using zinc finger nucleases. <b>2013</b> , e50957	21
1175	Cholestatic jaundice as a result of combination designer supplement ingestion. <b>2013</b> , 47, e33	9
1174	Alkaline phosphatase: the next independent predictor of the poor 90-day outcome in alcoholic hepatitis. <b>2013</b> , 2013, 614081	7

1173	Acute cholestatic hepatitis a virus infection presenting with hemolytic anemia and renal failure: a case report. <b>2013</b> , 2013, 438375	4
1172	Vitamin D in chronic liver disease. <b>2013</b> , 33, 338-52	101
1171	Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. <b>2013</b> , 33, 1029-38	20
1170	Tired of being tired. <b>2013</b> , 22, 289-90	
1169	Current concepts in the diagnosis and management of autoimmune hepatitis. <b>2013</b> , 4, 2-11	1
1168	Cholestatic pruritus: a retrospective analysis on clinical characteristics and treatment response. <b>2013</b> , 11, 158-68	10
1167	A Retrospective, Multi-Center, Post-Marketing Observational Study to Evaluate the Effectiveness of Ademetionine 1,4-Butanedisulfonate Injection (Transmetil® ) Treatment in Chinese Patients with Intrahepatic Cholestasis Caused by Viral Hepatitis. <b>2013</b> , 2, 71-80	
1166	Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. <b>2013</b> , 58, 2045-55	359
1165	The road to developing clinical trials: the Barcelona Liver Unit's experience and the dedication to the dream. <b>2013</b> , 57, 857-66	2
1164	Os et foie. <b>2013</b> , 8, 1-8	
1163	Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. <b>2013</b> , 19, 1631-8	57
1162	Primary biliary cirrhosis is more severe in overweight patients. <b>2013</b> , 47, e28-32	23
1161	[Review of overlap syndromes in autoimmune liver diseases. Diagnostic and therapeutic difficulties]. <b>2013</b> , 154, 923-9	1
1160	Refractory pruritus in primary biliary cirrhosis. <b>2013</b> , 2013,	7
1159	Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: a case-based review. <b>2013</b> , 2013,	1
1158	Liver disease. 196-202	
1157	Bile Salts. <b>2013</b> , 167-171	2
1156	Primary sclerosing cholangitis: diagnosis and treatment. <b>2013</b> , 110, 867-74	14



1155	Diagnosis and management of the overlap syndromes of autoimmune hepatitis. <b>2013</b> , 27, 417-23	45
1154	TRAF1-C5 affects quality of life in patients with primary biliary cirrhosis. <b>2013</b> , 2013, 510547	8
1153	25.2 Spezielle Differenzialdiagnose des Ikterus. <b>2013</b> ,	
1152	Hepatic inflammation and progressive liver fibrosis in chronic liver disease. <b>2014</b> , 20, 2515-32	213
1151	Osteoporosis in primary biliary cirrhosis of the liver. <b>2014</b> , 9, 82-7	20
1150	Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. <b>2014</b> , 28, 23-30	31
1149	Problem-solving combined with ultrasonography: a strategy for internists to improve case management and reduce diagnostic errors. <b>2014</b> , 8, 11	
1148	. <b>2014</b> ,	5
1147	Predicting outcome in primary biliary cirrhosis. <b>2014</b> , 13, 316-326	30
1146	Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. <b>2014</b> , 13, 384-389	8
1145	Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. <b>2014</b> , 44 Suppl S1, 71-90	64
1144	Angiogenesis-related biomarkers in patients with alcoholic liver disease: their association with liver disease complications and outcome. <b>2014</b> , 2014, 673032	9
1143	Genetics and epigenetics of primary biliary cirrhosis. <b>2014</b> , 34, 255-64	35
1142	Old and novel therapies for primary biliary cirrhosis. <b>2014</b> , 34, 341-51	21
1141	A clinical approach to intrahepatic cholestasis of pregnancy. <b>2014</b> , 31, 1-8	35
1140	The association between bile salt export pump single-nucleotide polymorphisms and primary biliary cirrhosis susceptibility and ursodeoxycholic acid response. <b>2014</b> , 2014, 350690	4
1139	Cystic fibrosis related liver disease--another black box in hepatology. <b>2014</b> , 15, 13529-49	37
1138	Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. <b>2014</b> , 49, 901-8	63

1137	Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. <b>2014</b> , 32, 631-6	15
1136	Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. <b>2014</b> , 2014, 127831	18
1135	Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. <b>2014</b> , 59, 242-50	59
1134	Reply to: "AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis". <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1445-6	13.4
1133	AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1443-5	13.4 30
1132	Benigne Gallenwegserkrankungen. <b>2014</b> , 8, 393-410	
1131	Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required?. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 965-6	13.4 4
1130	Hepatologische Erkrankungen in der Schwangerschaft. <b>2014</b> , 8, 25-40	0
1129	Changing epidemiology and natural history of primary biliary cirrhosis. <b>2014</b> , 3, 12-14	3
1128	Chronologic changes of explanted liver volume and the use of ursodeoxycholic acid in patients with end-stage primary biliary cirrhosis. <b>2014</b> , 44, 993-9	1
1127	Autophagy - another piece of the puzzle towards understanding primary biliary cirrhosis?. <b>2014</b> , 34, 481-3	5
1126	Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon. <b>2014</b> , 3, 83-85	1
1125	Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?. <b>2014</b> , 3, 29-33	7
1124	Diagnosis and management of patients with primary biliary cirrhosis. <b>2014</b> , 3, 52-55	8
1123	Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. <b>2014</b> , 147, 1338-49.e5; quiz e15	265
1122	Soluble intracellular adhesion molecule, M30 and M65 as serum markers of disease activity and prognosis in cholestatic liver diseases. <b>2014</b> , 44, 1286-98	18
1121	Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. <b>2014</b> , 39, 282-301	57
1120	Medical management of primary sclerosing cholangitis. <b>2014</b> , 3, 48-51	2

1119	Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis. <b>2014</b> , 34, 220-6	13
1118	Immunosuppressive therapy for primary biliary cirrhosis: Do we need in future?. <b>2014</b> , 44, 935-6	
1117	Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy. <b>2014</b> , 44, 947-55	16
1116	Intrahepatic cholestasis of pregnancy: Diagnosis and management. <b>2014</b> , 4, 58-61	7
1115	Overlap syndromes. <b>2014</b> , 3, 2-5	9
1114	Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). <b>2014</b> , 60, 785-8	32
1113	Primary biliary cirrhosis: overlaps with other autoimmune disorders. <b>2014</b> , 34, 352-60	36
1112	Advances in pathogenesis and management of pruritus in cholestasis. <b>2014</b> , 32, 637-45	45
1111	Evidence-based treatment of primary biliary cirrhosis. <b>2014</b> , 32, 626-30	5
1110	Monitoring and Care. <b>2014</b> , 478-493	
1109	Fibrate treatment for primary biliary cirrhosis. <b>2014</b> , 30, 279-86	28
1108	Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. <b>2014</b> , 26, 532-7	21
1107	Hepatobiliary manifestations of inflammatory bowel disease. <b>2014</b> , 20, 1655-67	17
1106	Primary sclerosing cholangitis. <b>2014</b> , 32, 438-45	34
1105	Treatment of primary biliary cirrhosis. <b>2014</b> , 2, 11-25	
1104	Clinical significance of autoantibodies in primary biliary cirrhosis. <b>2014</b> , 34, 334-40	41
1103	The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis. <b>2014</b> , 52, 1533-42	26
1102	Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. <b>2014</b> , 15, 660-8	9

1101	Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis. <b>2014</b> , 44, 1206-14		18
1100	Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. <b>2014</b> , 34, 197-203		71
1099	Bile acid receptors as targets for drug development. <b>2014</b> , 11, 55-67		423
1098	Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis. <b>2014</b> , 25, 230-4		4
1097	Receptors, cells and circuits involved in pruritus of systemic disorders. <b>2014</b> , 1842, 869-92		62
1096	Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis. <b>2014</b> , 46, 625-31		24
1095	PSC: Novel disease associations providing pathogenetic clues?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 687-8	13.4	1
1094	Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma. <b>2014</b> , 59, 1322-9		25
1093	Cholangiocarcinoma. <b>2014</b> , 383, 2168-79		981
1092	Liver involvement in patients with brucellosis: results of the Marmara study. <b>2014</b> , 33, 1253-62		19
1091	Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. <b>2014</b> , 46, 363-8		11
1090	Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. <b>2014</b> , 60, 931-40		72
1089	Update on Malnutrition in Liver Cirrhosis: Assessment and Treatment. <b>2014</b> , 13, 24-34		3
1088	Les h�patopathies cholestastiques chroniques. <b>2014</b> , 35, A2-A5		
1087	Primary Sclerosing Cholangitis. <b>2014</b> , 925-936		
1086	Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1010-6	13.4	72
1085	Cholestatic phenotypes of autoimmune hepatitis. <b>2014</b> , 12, 1430-8		41
1084	Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis. <b>2014</b> , 12, 863-9		50

1083	Autoimmune liver disease, autoimmunity and liver transplantation. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 210-234	139
1082	Bile acids reach out to the spinal cord: new insights to the pathogenesis of itch and analgesia in cholestatic liver disease. <b>2014</b> , 59, 1638-41	14
1081	Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. <b>2014</b> , 59, 1954-63	121
1080	Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. <b>2014</b> , 39, 879-86	24
1079	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. <b>2014</b> , 65, 174-86	18
1078	Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. <b>2014</b> , 34, e31-8	70
1077	Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease. <b>2014</b> , 34, 1488-95	28
1076	[Are antimitochondrial antibodies the invariable hallmark of primary biliary cirrhosis?]. <b>2014</b> , 43, 1311-3	2
1075	La cholestase gravidique. <b>2014</b> , 13, 167-170	
1074	Cholestatic Liver Disease. <b>2014</b> ,	6
1073	Gastrointestinal involvement in systemic sclerosis. <b>2014</b> , 43, e279-91	43
1072	Gallengangsstenosen. <b>2014</b> , 9, 473-481	
1071	Immunologic derangement preceding clinical autoimmunity. <b>2014</b> , 23, 1305-8	4
1070	The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. <b>2014</b> , 147, 1417-28	157
1069	Diagnosis and classification of primary sclerosing cholangitis. <b>2014</b> , 13, 445-50	42
1068	The diagnosis of primary biliary cirrhosis. <b>2014</b> , 13, 441-4	101
1067	Cholestase [Update 2014]. <b>2014</b> , 8, 73-90	
1066	Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years. <b>2014</b> , 8, 266-74	18

1065	ABCB4: Insights from pathobiology into therapy. <b>2014</b> , 38, 557-63		17
1064	[Primary biliary cirrhosis and pregnancy]. <b>2014</b> , 43, 335-41		5
1063	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1249-58	13.4	92
1062	Autoantibodies in primary biliary cirrhosis: antinuclear envelope autoantibodies. <b>2014</b> , 38, 256-8		2
1061	Time to say goodbye to the drug or the model? - why do drugs fail to live up to their promise in bile duct ligated mice?. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 12-5	13.4	4
1060	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1290-303	13.4	96
1059	Role of liver biopsy in autoimmune liver disease. <b>2014</b> , 20, 109-118		9
1058	Role of genetics in diagnosis and therapy of acquired liver disease. <b>2014</b> , 37, 15-34		5
1057	Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. <b>2014</b> , 12, 1733-8		54
1056	Primary biliary cirrhosis in adults. <b>2014</b> , 8, 427-33		25
1055	Pruritus in cholestasis: facts and fiction. <b>2014</b> , 60, 399-407		129
1054	Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients. <b>2014</b> , 5, e56		33
1053	Pregnancy in women with primary biliary cirrhosis. <b>2014</b> , 13, 931-5		33
1052	Primary biliary cirrhosis and primary sclerosing cholangitis and nutrition. <b>2014</b> , 273-279		
1051	Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis. <b>2014</b> , 93, e104		8
1050	Osteoporoza w mukowiscydozie/ Osteoporosis in cystic fibrosis. <b>2015</b> , 29, 39-44		
1049	Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. <b>2015</b> , 62, 1731-41		38
1048	Primary biliary "cirrhosis": time to replace a misnomer. <b>2015</b> , 61, 1091		0

1047	PWE-107 Bone disease in primary biliary cirrhosis Is the risk higher than previously thought?. <b>2015</b> , 64, A259.2-A259	1
1046	PWE-106 Is functional sarcopenia associated with hepatic encephalopathy and severity of cirrhosis?. <b>2015</b> , 64, A259.1-A259	
1045	Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. <b>2015</b> , 5, 13462	56
1044	Drug treatment of pruritus in liver diseases. <b>2015</b> , 15, 351-7	24
1043	Jaundice associated pruritis: a review of pathophysiology and treatment. <b>2015</b> , 21, 1404-13	24
1042	Variant adiponutrin confers genetic protection against cholestatic itch. <b>2014</b> , 4, 6374	6
1041	Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat. <b>2015</b> , 33 Suppl 2, 140-8	30
1040	Autoimmune Lebererkrankungen und deren Berlappungssyndrome. <b>2015</b> , 10, 325-334	
1039	Reply: To PMID 24923261. <b>2015</b> , 61, 1435	
1038	Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. <b>2015</b> , 62, 1620-2	92
1037	Preparation of ursodeoxycholic acid from 7-ketone lithocholic acid by stereoselective electroreduction. <b>2015</b> , 2,	2
1036	Primary biliary cirrhosis: time to replace a misnomer. <b>2015</b> , 61, 1435	
1035	PWE-108 National survey of ascitic fluid wbc analysis method in the diagnosis of spontaneous bacterial peritonitis. <b>2015</b> , 64, A259.3-A260	
1034	How Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?. <b>2015</b> , 31, 173-7	3
1033	Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis. <b>2015</b> , 35, 636-41	40
1032	Biomarkers for disease progression of primary sclerosing cholangitis. <b>2015</b> , 31, 239-46	14
1031	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <b>2015</b> , 62, 188-97	76
1030	Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. <b>2015</b> , 42, 221-30	30

1029	The role of rosuvastatin in experimentally induced hepatic cholestasis in adult male albino rats. <b>2015</b> , 38, 219-227	1
1028	Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases. <b>2015</b> , 94, e1243	11
1027	Autoimmune liver diseases: internist's guide from bench to bedside. <b>2015</b> , 9, 20	
1026	Orphan drugs in development for primary biliary cirrhosis: challenges and progress. <b>2015</b> , 83	
1025	Gallbladder carcinoma: Prognostic factors and therapeutic options. <b>2015</b> , 21, 12211-7	124
1024	A Concise Review of Autoimmune Liver Diseases. <b>2015</b> ,	3
1023	Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. <b>2015</b> , 7, 926-41	61
1022	Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome: a meta-analysis. <b>2015</b> , 9, 567-74	10
1021	Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice. <b>2015</b> , 7, 3372-87	13
1020	PWE-105 Long term survival of cirrhotics following icu admission in a subgroup of patients with 'resilient' cirrhosis. <b>2015</b> , 64, A258.2-A259	1
1019	Role of vitamins in gastrointestinal diseases. <b>2015</b> , 21, 5191-209	35
1018	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <b>2015</b> , 10, e0140525	6
1017	Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. <b>2015</b> , 9, 2757-66	20
1016	Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver. <b>2015</b> , 52 Suppl 1, 15-46	8
1015	Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development. <b>2015</b> , 3, 53-66	81
1014	Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis. <b>2015</b> ,	1
1013	Rapid progression of primary sclerosing cholangitis complicated with ulcerative colitis. <b>2015</b> , 2015, 125718	
1012	Management of pruritus in chronic liver disease. <b>2015</b> , 2015, 295891	16



1011	Primary sclerosing cholangitis and the role of the clinical nurse specialist. <b>2015</b> , 13, 36-45		3
1010	EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 237-64	13.4	1082
1009	Clinical value of maternal bile Acid quantification in intrahepatic cholestasis of pregnancy as an adverse perinatal outcome predictor. <b>2015</b> , 79, 222-8		20
1008	Liver Transplantation for Patients with Cholestatic Liver Diseases. <b>2015</b> , 31, 194-8		6
1007	Fetal complications due to intrahepatic cholestasis of pregnancy. <b>2015</b> , 43, 133-9		20
1006	Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease. <b>2015</b> , 9, 177-84		22
1005	Should hepatocellular carcinoma screening with ultrasound be recommended in hepatocellular carcinoma high-incidence areas?. <b>2015</b> , 61, 1091-2		1
1004	Overlap Syndromes. <b>2015</b> , 33 Suppl 2, 181-7		18
1003	RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. <b>2015</b> , 5, e007985		14
1002	Cirrhose biliaire primitive : propos de 2 cas Evolution sive au Sigeal. <b>2015</b> , 9, 163-165		1
1001	Rifampin (INN Rifampicin). <b>2015</b> , 50, 891-5		6
1000	Intrahepatic cholestasis of pregnancy: observational study of the treatment with low-dose ursodeoxycholic acid. <b>2015</b> , 15, 92		9
999	Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. <b>2015</b> , 39, e57-9		29
998	IgG4-Associated Cholangitis--A Mimic of PSC. <b>2015</b> , 33 Suppl 2, 176-80		18
997	Diagnosis, Differential Diagnosis, and Epidemiology of Primary Sclerosing Cholangitis. <b>2015</b> , 33 Suppl 2, 134-9		15
996	Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. <b>2015</b> , 33 Suppl 2, 125-33		9
995	Pathogenesis and Management of Pruritus in PBC and PSC. <b>2015</b> , 33 Suppl 2, 164-75		47
994	Aspects of the Pathophysiology of Primary Biliary Cirrhosis. <b>2015</b> , 33 Suppl 2, 102-8		6

993	Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis. <b>2015</b> , 33 Suppl 2, 118-24	2
992	Worldwide Incidence of Autoimmune Liver Disease. <b>2015</b> , 33 Suppl 2, 2-12	65
991	Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report. <b>2015</b> , 47, 2775-7	3
990	Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow. <b>2015</b> , 33 Suppl 2, 149-63	26
989	Bile duct tumors. <b>2015</b> , 57, 101-12	2
988	Advances in pharmacotherapy for primary biliary cirrhosis. <b>2015</b> , 16, 633-43	25
987	Who and how to screen for cancer in at-risk inflammatory bowel disease patients. <b>2015</b> , 9, 731-46	8
986	Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography. <b>2015</b> , 35, 254-62	25
985	Study of trace elements in liver cirrhosis patients and their role in prognosis of disease. <b>2015</b> , 165, 35-40	52
984	Novel therapeutic targets in primary biliary cirrhosis. <b>2015</b> , 12, 147-58	94
983	Bone disorders. <b>2015</b> , 283-290	
982	Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. <b>2015</b> , 50, 675-82	30
981	Primary biliary cirrhosis: safety and benefits of established and emerging therapies. <b>2015</b> , 14, 1435-44	6
980	Overlap syndromes of autoimmune hepatitis: diagnosis and treatment. <b>2015</b> , 80, 150-159	2
979	Pancreatic involvement in pediatric inflammatory bowel diseases. <b>2015</b> , 11, 207-11	7
978	Autoantibodies to asialoglycoprotein receptor (ASGPR) in patients with autoimmune liver diseases. <b>2015</b> , 450, 1-5	15
977	The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. <b>2015</b> , 9, 342-8	84
976	Functional and structural features of cholangiocytes in health and disease. <b>2015</b> , 1, 368-380	60

975	Primary sclerosing cholangitis: a clinical update. <b>2015</b> , 114, 53-64		31
974	Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. <b>2015</b> , 13, 2372-9		11
973	Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. <b>2015</b> , 33, 433-9		31
972	Primary biliary cirrhosis: proposal for a new simple histological scoring system. <b>2015</b> , 35, 652-9		16
971	Towards the serological diagnosis of primary biliary cirrhosis. <b>2015</b> , 35, 299-301		0
970	New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S25-37	13.4	306
969	Primary sclerosing cholangitis - the Norwegian experience. <b>2015</b> , 50, 781-96		7
968	Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 897-904	13.4	48
967	Bile duct tumors. <b>2015</b> , 57, 101-112		
966	Unmet challenges in immune-mediated hepatobiliary diseases. <b>2015</b> , 48, 127-31		26
965	Characterization and treatment of persistent hepatocellular secretory failure. <b>2015</b> , 35, 1478-88		19
964	Epidemiology of cholangiocarcinoma. <b>2015</b> , 29, 221-32		242
963	New simple prognostic score for primary biliary cirrhosis: Albumin-bilirubin score. <b>2015</b> , 30, 1391-6		69
962	Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis. <b>2015</b> , 45, 846-55		22
961	The Cholangiopathies. <b>2015</b> , 90, 791-800		128
960	Screening for malignancy in primary sclerosing cholangitis (PSC). <b>2015</b> , 17, 17		34
959	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <b>2015</b> , 35, 381-90		90
958	Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. <b>2015</b> , 47, 696-702		54

957	Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. <b>2015</b> , 110, 1536-8		26
956	Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. <b>2015</b> , 47, 924-6		14
955	Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. <b>2015</b> , 149, 1627-9		56
954	Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. <b>2015</b> , 13, 1867-9		14
953	Clinical and biochemical assessment of symptomatic and asymptomatic liver disease. <b>2015</b> , 43, 557-561		2
952	Assessment of health-related quality of life and related factors in patients with chronic liver disease. <b>2015</b> , 19, 590-5		16
951	Autoimmune hepatitis and overlap syndromes. <b>2015</b> , 43, 639-644		
950	Primary sclerosing cholangitis. <b>2015</b> , 43, 648-652		3
949	Applicability and prognostic value of histologic scoring systems in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1212-9	13.4	42
948	Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease. <b>2015</b> , 41, 393-405		21
947	Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis. <b>2015</b> , 35, 1764-71		23
946	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <b>2015</b> , 149, 1804-1812.e4		235
945	Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1285-7	13.4	55
944	Primary biliary cirrhosis. <b>2015</b> , 43, 645-647		2
943	Complications of cholestasis. <b>2015</b> , 43, 666-668		1
942	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1449-58	13.4	69
941	Estrogen-Induced Cholestasis Leads to Repressed CYP2D6 Expression in CYP2D6-Humanized Mice. <b>2015</b> , 88, 106-12		20
940	Oleanolic acid attenuates obstructive cholestasis in bile duct-ligated mice, possibly via activation of NRF2-MRPs and FXR antagonism. <b>2015</b> , 765, 131-9		26

939	A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. <b>2015</b> , 14, 413-21		19
938	Autophagy and senescence in fibrosing cholangiopathies. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 934-45	13.4	59
937	Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <b>2015</b> , 6, e109		16
936	Management of intrahepatic cholestasis of pregnancy. <b>2015</b> , 9, 1273-9		20
935	Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. <b>2015</b> , 64, 1671-2		22
934	Overlap syndromes of autoimmune hepatitis: diagnosis and treatment. <b>2015</b> , 80, 150-9		6
933	EASL Clinical Practice Guidelines: Autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 971-1004	13.4	580
932	Primary biliary cirrhosis. <b>2015</b> , 386, 1565-75		325
931	Diagnosis and management of overlap syndromes. <b>2015</b> , 19, 81-97		23
930	New therapies for primary biliary cirrhosis. <b>2015</b> , 48, 263-72		28
929	Endoscopy in Inflammatory Bowel Disease. <b>2015</b> ,		
928	The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation. <b>2015</b> , 67, 36-73		100
927	Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis. <b>2015</b> , 45, 48-58		15
926	Autoantibody profiling of patients with primary biliary cirrhosis using a multiplexed line-blot assay. <b>2015</b> , 438, 135-8		21
925	Unmet clinical need in autoimmune liver diseases. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 208-18	13.4	44
924	TGR5: pathogenetic role and/or therapeutic target in fibrosing cholangitis?. <b>2015</b> , 48, 218-25		34
923	Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. <b>2015</b> , 212, 100.e1-7		116
922	Imaging approach to hepatocellular carcinoma, cholangiocarcinoma, and metastatic colorectal cancer. <b>2015</b> , 24, 19-40		9

921	Maternale Erkrankungen in der Schwangerschaft. <b>2016</b> , 347-618	
920	Liver damage in primary biliary cirrhosis and accompanied by primary Sjögren's syndrome: a retrospective pilot study. <b>2016</b> , 41, 182-7	4
919	Cirrhosis and autoimmune liver disease: Current understanding. <b>2016</b> , 8, 1157-1168	37
918	Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis. <b>2016</b> , 16, e38558	21
917	Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases. <b>2016</b> , 2016, 6597970	3
916	Diagnosis and Management of Cirrhosis-Related Osteoporosis. <b>2016</b> , 2016, 1423462	30
915	Ulcerative Colitis with and without Primary Sclerosing Cholangitis: Two Different Diseases?. <b>2016</b> , 1, 9-14	3
914	Vitamin D deficiency in patients with liver cirrhosis. <b>2016</b> , 29, 297-306	52
913	Sclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential Diagnosis. <b>2016</b> , 17, 25-38	33
912	Recent advances in the diagnosis and treatment of primary biliary cholangitis. <b>2016</b> , 8, 1419-1441	20
911	Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options. <b>2016</b> , 28, 508-13	22
910	Environmental Risk Factors of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis. <b>2016</b> , 62, 437-42	10
909	Serum Autotaxin Activity Correlates With Pruritus in Pediatric Cholestatic Disorders. <b>2016</b> , 62, 530-5	21
908	Primary biliary cholangitis associated with warm autoimmune hemolytic anemia. <b>2016</b> , 17, 128-31	4
907	The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. <b>2016</b> , 63, 930-50	184
906	Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. <b>2016</b> , 64, 501-7	69
905	It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology. <b>2016</b> , 46, 407-15	5
904	Bile duct basement membrane thickening in primary sclerosing cholangitis. <b>2016</b> , 68, 819-24	6

903	Risk factors for primary sclerosing cholangitis. <b>2016</b> , 36, 84-91	15
902	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <b>2016</b> , 63, 1357-67	94
901	Consensus on the diagnosis and treatment of cholestatic liver diseases (2015, China). <b>2016</b> , 17, 137-54	1
900	Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <b>2016</b> , 185, 61-71	59
899	Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis. <b>2016</b> , 65, 1230-2	20
898	[Cholestatic liver disease]. <b>2016</b> , 141, 1683-1687	1
897	Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion. <b>2016</b> , 7, 240-245	1
896	Cholestatic Liver Injury: Care of Patients With Primary Biliary Cholangitis or Primary Sclerosing Cholangitis. <b>2016</b> , 27, 441-452	5
895	Surveillance in cholangiocellular carcinoma. <b>2016</b> , 30, 987-999	19
894	Intrahepatic cholestasis of pregnancy (ICP): case report and review of the literature. <b>2016</b> , 54, 1327-1333	19
893	The Microbiome and Primary Sclerosing Cholangitis. <b>2016</b> , 36, 340-348	12
892	Vigilancia del colangiocarcinoma en pacientes con colangitis esclerosante primaria: ¿es efectiva y est]ustificada?. <b>2016</b> , 8, S20-S24	
891	A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. <b>2016</b> , 95, e5391	15
890	Screening for liver fibrosis in the general population: a call for action. <b>2016</b> , 1, 256-260	81
889	Targets and investigative treatments for primary biliary cholangitis. <b>2016</b> , 4, 1011-1020	
888	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. <b>2016</b> , 22, 42-52	78
887	Colangitis biliar primaria. <b>2016</b> , 12, 561-567	
886	Novel bile acid therapeutics for the treatment of chronic liver diseases. <b>2016</b> , 9, 376-91	36

885	Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. <b>2016</b> , 63, 185-96	134
884	Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic patients. <b>2016</b> , 7, 5-7	4
883	Red Blood Cell Distribution Width to Platelet Ratio is Related to Histologic Severity of Primary Biliary Cirrhosis. <b>2016</b> , 95, e3114	26
882	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <b>2016</b> , 13, 261-80	618
881	Osteoporosis in liver disease: pathogenesis and management. <b>2016</b> , 7, 128-35	44
880	Novel Aspects in the Management of Cholestatic Liver Diseases. <b>2016</b> , 34, 340-6	10
879	Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). <b>2016</b> , 128, 679-690	26
878	The diagnosis of antimitochondrial antibody-negative primary biliary cholangitis. <b>2016</b> , 40, 553-561	17
877	Itch Management: Physical Approaches (UV Phototherapy, Acupuncture). <b>2016</b> , 50, 54-63	6
876	Cholestatic Itch Management. <b>2016</b> , 50, 142-8	7
875	Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis. <b>2016</b> , 42, 2146-55	12
874	The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. <b>2016</b> , 44, 1039-1050	41
873	[Pruritus in systemic diseases : Common and rare etiologies]. <b>2016</b> , 67, 606-14	2
872	Cutting edge issues in autoimmune hepatitis. <b>2016</b> , 75, 6-19	75
871	IBD: A timely diagnosis of primary sclerosing cholangitis in IBD. <b>2016</b> , 13, 565-6	1
870	Advances in primary sclerosing cholangitis. <b>2016</b> , 1, 68-77	15
869	Molecular diagnostic testing for primary biliary cholangitis. <b>2016</b> , 16, 1001-10	20
868	The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. <b>2016</b> , 43, 294-302	41



867	Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. <b>2016</b> , 70, 302-11	10
866	Obeticholic acid for the treatment of primary biliary cholangitis. <b>2016</b> , 17, 1809-15	29
865	Diagnostic yield of endomicroscopy for dysplasia in primary sclerosing cholangitis associated inflammatory bowel disease: a feasibility study. <b>2016</b> , 4, E901-11	8
864	Primary Biliary Cholangitis--A New Name and a New Treatment. <b>2016</b> , 375, 685-7	9
863	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <b>2016</b> , 375, 631-43	574
862	Obeticholic acid for the treatment of primary biliary cirrhosis. <b>2016</b> , 10, 1091-1099	8
861	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2016</b> , 27, v28-v37	318
860	IgG4-related hepatobiliary disease: an overview. <b>2016</b> , 13, 601-12	45
859	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <b>2016</b> , 14, 1806-1812	8
858	Surveillance for Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis: Effective and Justified?. <b>2016</b> , 8, 43-47	15
857	Primary Sclerosing Cholangitis. <b>2016</b> , 375, 1161-70	240
856	Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. <b>2016</b> , 10, 909-915	27
855	Further evidence that a variant of the gene NUDT15 may be an important predictor of azathioprine-induced toxicity in Chinese subjects: a case report. <b>2016</b> , 41, 572-4	12
854	Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. <b>2016</b> , 61, 3037-3044	50
853	Clonal Characteristics of Circulating B Lymphocyte Repertoire in Primary Biliary Cholangitis. <b>2016</b> , 197, 1609-20	17
852	EUS in liver disease. <b>2016</b> , 217-224	
851	[A 22-year-old mother with severe pruritus and increasing jaundice two weeks after starting hormonal contraception]. <b>2016</b> , 54, 1076-80	3
850	Clinical Vignettes/Case Reports - Liver. <b>2016</b> , 111, S847-S967	19

849	Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. <b>2016</b> , 6, 30847		32
848	Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics. <b>2016</b> , 6, 311-318		18
847	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial. <b>2016</b> , 16, 71		21
846	Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France. <b>2016</b> , 28, e26-32		6
845	Postoperative Care of a Liver Transplant Recipient Using a Classification System: Type A (Stable) Versus Type B (Unstable). <b>2016</b> , 39, 252-66		
844	Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management. <b>2016</b> , 9, 25-9		3
843	[Management of pruritus in patients with cholestatic liver disease]. <b>2016</b> , 158, 64-7		2
842	Testing for Anti-PBP Antibody Is Not Useful in Diagnosing Autoimmune Pancreatitis. <b>2016</b> , 111, 1650-1654		7
841	Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1217-1231	13.4	56
840	Immunology of hepatic diseases during pregnancy. <b>2016</b> , 38, 669-685		13
839	Nutritional evaluation of children with chronic cholestatic disease. <b>2016</b> , 92, 197-205		
838	Evidence-based clinical practice guidelines for liver cirrhosis 2015. <b>2016</b> , 51, 629-50		216
837	Toward precision medicine in primary biliary cholangitis. <b>2016</b> , 48, 843-50		9
836	Patología inflamatoria y autoinmune de la vía biliar. <b>2016</b> , 12, 442-450		
835	Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. <b>2016</b> , 4, 562-9		17
834	Varón de 40 años con síndrome general, prurito y aumento de perímetro abdominal. <b>2016</b> , 12, 596.e1-596.e4		
833	Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. <b>2016</b> , 34, 580-8		30
832	Increased frequency of double and triple heterozygous gene variants in children with intrahepatic cholestasis. <b>2016</b> , 46, 306-11		11

831	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <b>2016</b> , 65, 321-9	107
830	The pathophysiology of intrahepatic cholestasis of pregnancy. <b>2016</b> , 40, 141-53	84
829	Pregnancy and liver disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 933-45	13.4 131
828	Obeticholic acid for the treatment of primary biliary cirrhosis. <b>2016</b> , 9, 13-26	42
827	Assessment of liver fibrosis in primary biliary cholangitis: Comparison between indirect serum markers and fibrosis morphometry. <b>2016</b> , 48, 298-301	8
826	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. <b>2016</b> , 63, 644-59	43
825	Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid. <b>2016</b> , 36, 15-26	14
824	New Therapeutic Strategies for Primary Sclerosing Cholangitis. <b>2016</b> , 36, 5-14	35
823	Emerging drugs for the treatment of Primary Biliary Cholangitis. <b>2016</b> , 21, 39-56	14
822	Child with Jaundice and Pruritus: How to Evaluate?. <b>2016</b> , 83, 1311-1320	7
821	Nutritional evaluation of children with chronic cholestatic disease. <b>2016</b> , 92, 197-205	10
820	Scleroderma and liver disease: a case of an association with primary sclerosing cholangitis. <b>2016</b> , 45, 334-5	1
819	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <b>2016</b> , 10, 239-54	354
818	Proposed therapies in primary biliary cholangitis. <b>2016</b> , 10, 371-382	8
817	Making Sense of Autoantibodies in Cholestatic Liver Diseases. <b>2016</b> , 20, 33-46	17
816	New Thoughts on Immunoglobulin G4-Related Sclerosing Cholangitis. <b>2016</b> , 20, 47-65	10
815	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. <b>2016</b> , 20, 131-42	13
814	The management of autoimmunity in patients with cholestatic liver diseases. <b>2016</b> , 10, 73-91	8

813	Cancer Risk and Surveillance in Primary Sclerosing Cholangitis. <b>2016</b> , 20, 79-98	36
812	Functional gadoxetate disodium-enhanced MRI in patients with primary sclerosing cholangitis (PSC). <b>2016</b> , 26, 1116-24	18
811	A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. <b>2016</b> , 7, 158-166	20
810	Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis. <b>2016</b> , 46, 277-91	9
809	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. <b>2017</b> , 66, 611-619	216
808	Update on pharmacotherapies for cholestatic liver disease. <b>2017</b> , 1, 7-17	12
807	The interrelationship between bile acid and vitamin A homeostasis. <b>2017</b> , 1862, 496-512	34
806	Diagnostic considerations for cholestatic liver disease. <b>2017</b> , 32, 1303-1309	22
805	[Intrahepatic cholestasis of pregnancy : Rare but important]. <b>2017</b> , 68, 95-102	12
804	Management of cholestatic disease in 2017. <b>2017</b> , 37 Suppl 1, 123-129	45
803	The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210. <b>2017</b> , 45, 733-743	38
802	Primary Biliary Cholangitis Associated with Skin Disorders: A Case Report and Review of the Literature. <b>2017</b> , 65, 299-309	9
801	Bile acids and cardiovascular function in cirrhosis. <b>2017</b> , 37, 1420-1430	26
800	Increases in IgE, Eosinophils, and Mast Cells Can be Used in Diagnosis and to Predict Relapse of IgG4-Related Disease. <b>2017</b> , 15, 1444-1452.e6	69
799	Equitable distribution in rare indications for liver transplantation: the dilemma of the too small tablecloth continues!. <b>2017</b> , 30, 451-453	2
798	Role of nuclear medicine in diagnosis and management of hepatopancreatobiliary disease. <b>2017</b> , 285-315.e3	2
797	Primary biliary cholangitis: new treatments for an old disease. <b>2017</b> , 8, 29-36	6
796	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study. <b>2017</b> , 37, 1554-1561	39

795	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <b>2017</b> , 152, 1975-1984.e8		219
794	Biologie des maladies cholestatiques chroniques de l'adulte. <b>2017</b> , 2017, 34-44		
793	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1214-1222	13.4	34
792	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. <b>2017</b> , 389, 1114-1123		110
791	An appealing new agent for treating cholestatic pruritus. <b>2017</b> , 389, 1078-1080		
790	Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. <b>2017</b> , 66, 528-541		51
789	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. <b>2017</b> , 130, 744.e1-744.e7		20
788	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. <b>2017</b> , 62, 1363-1372		3
787	Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. <b>2017</b> , 66, 137-144		40
786	Management and follow-up of gallbladder polyps : Joint guidelines between the European Society of Gastrointestinal and Abdominal Radiology (ESGAR), European Association for Endoscopic Surgery and other Interventional Techniques (EAES), International Society of Digestive Surgery - European Federation (EFISDS) and European Society of Gastrointestinal Endoscopy (ESGE). <b>2017</b> , 37, 2056-2066		102
785	Decreased serum DNase1-activity in patients with autoimmune liver diseases. <b>2017</b> , 50, 125-132		4
784	Emerging treatments for primary sclerosing cholangitis. <b>2017</b> , 11, 451-459		11
783	Physical Chemistry of Bile: Detailed Pathogenesis of Cholelithiasis. <b>2017</b> , 33, 229-236		3
782	A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. <b>2017</b> , 8, 14828		66
781	Emerging pharmacologic therapies for primary sclerosing cholangitis. <b>2017</b> , 33, 149-157		10
780	EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 145-172	13.4	512
779	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1265-1281	13.4	62
778	Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis. <b>2017</b> , 3, CD011343		17

777	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <b>2017</b> , 49, 588-608	94
776	[Extracorporeal therapies in hepatic diseases]. <b>2017</b> , 112, 444-453	
775	What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?. <b>2017</b> , 35, 359-366	8
774	Comprehensive Review on Colorectal Cancer and Transplant. <b>2017</b> , 17, 2761-2774	9
773	Pathological Features of Biliary Disease in Children and Adults. <b>2017</b> , 43-61	
772	Primary Biliary Cholangitis: Its Science and Practice. <b>2017</b> , 129-182	
771	Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. <b>2017</b> , 31, 187-198	26
770	The management of childhood liver diseases in adulthood. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 631-644	13.4 19
769	Autoimmune Hepatitis Overlap Syndromes and Liver Pathology. <b>2017</b> , 46, 345-364	12
768	Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: A systematic review. <b>2017</b> , 37, 1877-1886	21
767	Bile Acid-Induced Liver Injury in Cholestasis. <b>2017</b> , 143-172	3
766	Clinical usefulness of serum antibodies as biomarkers of gastrointestinal and liver diseases. <b>2017</b> , 49, 947-956	23
765	[Physiopathology and management of cholestatic pruritus in children]. <b>2017</b> , 24, 682-688	3
764	Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece. <b>2017</b> , 42, 81-88	28
763	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 549-558	13.4 138
762	Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. <b>2017</b> , 66, 1675-1688	63
761	Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. <b>2017</b> , 66, 1125-1143	148
760	Benign biliary diseases. <b>2017</b> , 93, 217-228	14

759	Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <b>2017</b> , 37, 159-174	21
758	Elevated trimethylamine--oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. <b>2017</b> , 5, 532-541	13
757	Bile Acids in Gastroenterology. <b>2017</b> ,	2
756	A Predictive 3D Multi-Scale Model of Biliary Fluid Dynamics in the Liver Lobule. <b>2017</b> , 4, 277-290.e9	50
755	Gender differences in liver disease and the drug-dose gender gap. <b>2017</b> , 120, 97-108	35
754	Sertraline as an Additional Treatment for Cholestatic Pruritus in Children. <b>2017</b> , 64, 431-435	30
753	Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. <b>2017</b> , 3, CD011648	8
752	Cholestatic Liver Diseases After Liver Transplant. <b>2017</b> , 21, 403-420	11
751	Primary Sclerosing Cholangitis (PSC): Current Concepts in Biology and Strategies for New Therapy. <b>2017</b> , 183-218	
750	[Overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis: First case in a context of autoimmunity and hypovitaminosis D]. <b>2017</b> , 46, 457-459	4
749	Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. <b>2017</b> , 28, 671-672	59
748	An update on cancer risk and surveillance in primary sclerosing cholangitis. <b>2017</b> , 37, 1103-1109	27
747	Liver Disease in Clinical Practice. <b>2017</b> ,	
746	Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 798-805	13.4 19
745	Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. <b>2017</b> , 62, 510-516	4
744	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. <b>2017</b> , 65, 1393-1404	114
743	Primary sclerosing cholangitis: a pre-malignant condition. <b>2017</b> , 15, 26-33	
742	Hepatopatias gravidas. <b>2017</b> , 21, 1-8	

741	Does transient elastography correlate with liver fibrosis in patients with PSC? Laennec score-based analysis of explanted livers. <b>2017</b> , 52, 1407-1412		11
740	Primary sclerosing cholangitis and the management of uncertainty and complexity. <b>2017</b> , 8, 260-266		5
739	Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. <b>2017</b> , 7, 10289		1
738	Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants. <b>2017</b> , 99, 350-356		1
737	[Chronic cholestatic liver diseases : Differential diagnosis, pathogenesis and current treatment in adults]. <b>2017</b> , 58, 805-825		1
736	Gallstone disease: Optimal timing of treatment. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 645-647	13.4	5
735	Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. <b>2017</b> , 16, 885-896		95
734	Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. <b>2018</b> , 67, 728-735		87
733	Risk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance. <b>2017</b> , 33, 78-84		16
732	Primary sclerosing cholangitis - a comprehensive review. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1298-1323	13.4	286
731	Lactation during cholestasis: Role of ABC proteins in bile acid traffic across the mammary gland. <b>2017</b> , 7, 7475		9
730	Primary Biliary Cholangitis. <b>2017</b> , 523-545		
729	Primary biliary cholangitis: a comprehensive overview. <b>2017</b> , 11, 485-499		65
728	[Practice guideline autoimmune liver diseases - AWMF-Reg. No. 021-27]. <b>2017</b> , 55, 1135-1226		24
727	Primary biliary cholangitis: symptoms, diagnosis and treatment. <b>2017</b> , 15, S12-S17		1
726	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <b>2017</b> , 8, e100		20
725	Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?. <b>2017</b> , 16, 124-129		12
724	Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. <b>2017</b> , 16, 119-123		11



723	A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients. <b>2017</b> , 10, 2	10
722	24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 446-447	13.4 3
721	Ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy: Results in real-world conditions and factors predictive of response to treatment. <b>2017</b> , 49, 63-69	22
720	Primary Sclerosing Cholangitis. <b>2017</b> ,	
719	Hepatic manifestations of inflammatory bowel diseases. <b>2017</b> , 37, 475-489	34
718	Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. <b>2017</b> , 37, 743-747	15
717	Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. <b>2017</b> , 52, 242-249	14
716	Diagnostic accuracy of two tests for determination of anti-m2 in the diagnosis of primary biliary cirrhosis: Is it possible to predict the course of the disease?. <b>2017</b> , 65, 299-306	1
715	Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. <b>2017</b> , 52, 483-493	23
714	A liver nodule in a patient transplanted for primary sclerosing cholangitis: an interdisciplinary diagnostic approach. <b>2017</b> , 55, 56-62	2
713	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. <b>2017</b> , 65, 152-163	57
712	Neues Therapiekonzept für die primär-biliäre Cholangitis (PBC). <b>2017</b> , 12, 69-70	
711	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <b>2017</b> , 65, 907-919	50
710	Imaging of autoimmune biliary disease. <b>2017</b> , 42, 3-18	9
709	CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. <b>2017</b> , 101, 589-597	6
708	Primary Sclerosing Cholangitis. <b>2017</b> , 489-522	1
707	The Liver in Pregnancy. <b>2017</b> , 244-267	
706	Primary sclerosing cholangitis: A review and update. <b>2017</b> , 1, 221-230	19

705	Autoimmunerkrankungen mit Leberbeteiligung. <b>2017</b> , 13, 331-346	
704	Anti-mitochondrial autoantibodies-milestone or byway to primary biliary cholangitis?. <b>2017</b> , 5, 50	2
703	13 Ikterus (II). <b>2017</b> ,	
702	Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study. <b>2017</b> , 4, e000177	1
701	Ursodeoxycholic Acid for the Treatment of Liver Diseases. <b>2017</b> , 767-779	
700	Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. <b>2017</b> , 23, 4548-4558	157
699	Primary sclerosing cholangitis. <b>2017</b> , 663-674.e5	1
698	Primary Sclerosing Cholangitis. <b>2017</b> , 13, 119-139	2
697	Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study. <b>2017</b> , 2017, 2185083	4
696	Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis. <b>2017</b> , 2017, 3073504	13
695	Changes in Etiologies of Hospitalized Patients with Liver Cirrhosis in Beijing 302 Hospital from 2002 to 2013. <b>2017</b> , 2017, 5605981	4
694	Serum Cytokine Levels and Their Relation to Clinical Features in Patients with Autoimmune Liver Diseases. <b>2017</b> , 2017, 9829436	15
693	Risk of liver disease in methotrexate treated patients. <b>2017</b> , 9, 1092-1100	58
692	New developments in the treatment of primary biliary cholangitis - role of obeticholic acid. <b>2017</b> , 13, 1053-1060	22
691	Translation and validation of the Serbian primary biliary cholangitis-40 questionnaire. <b>2017</b> , 12, e0175697	5
690	Apal polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. <b>2017</b> , 12, e0176264	10
689	Le malattie infiammatorie immuno-mediate (IMID) di interesse internistico: fisiopatologia, aspetti clinici e prospettive di terapia. <b>2017</b> , 5, 1	
688	New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin. <b>2018</b> , 31, 42-55	47

687	The role of ursodeoxycholic acid on cholestatic hepatic fibrosis in infant rats. <b>2018</b> , 17, 3837-3844	3
686	Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort. <b>2018</b> , 6, 247-254	8
685	Immune-mediated cholangitis: is it always nivolumab's fault?. <b>2018</b> , 67, 1325-1327	4
684	Editorial: alleviating the itch-the safety of rifampicin in the real world. <b>2018</b> , 47, 1332-1333	2
683	Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures. <b>2018</b> , 17, 143-151	1
682	Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study. <b>2018</b> , 53, 1151-1158	17
681	Primary Biliary Cholangitis. <b>2018</b> , 13, 171-179	
680	Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. <b>2018</b> , 68, 1174-1188	21
679	Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. <b>2018</b> , 19, 242-253	5
678	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. <b>2018</b> , 9, 87	39
677	Effect of deferred or no treatment with ursodeoxycholic acid in patients with early primary biliary cholangitis. <b>2018</b> , 48, 727-734	4
676	Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis. <b>2018</b> , 47, 886-895	41
675	Comprehensive review of autoantibodies in patients with hyper-IgM syndrome. <b>2018</b> , 15, 610-617	4
674	Primary sclerosing cholangitis. <b>2018</b> , 391, 2547-2559	139
673	Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. <b>2018</b> , 24, 269-276	3
672	Functional assessment of hepatobiliary secretion by C-cholylsarcosine positron emission tomography. <b>2018</b> , 1864, 1240-1244	8
671	A promising medium-term follow-up of pediatric sclerosing cholangitis: Mild phenotype or early diagnosis?. <b>2018</b> , 48, 556-565	1
670	Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination. <b>2018</b> , 53, 305-311	10

669	New therapies target the toxic consequences of cholestatic liver disease. <b>2018</b> , 12, 277-285		12
668	Hepatic Stem/Progenitor Cell Activation Differs between Primary Sclerosing and Primary Biliary Cholangitis. <b>2018</b> , 188, 627-639		40
667	Management of Chronic Hepatic Itch. <b>2018</b> , 36, 293-300		21
666	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 368-377	13.4	16
665	Gadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians?. <b>2018</b> , 73, 677.e1-677.e6		4
664	Management and treatment of gallbladder polyps. <b>2018</b> , 150, 487-491		2
663	The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. <b>2018</b> , 67, 1568-1594		122
662	Primary biliary cholangitis. <b>2018</b> , 151, 242-249		8
661	Pregnancy-associated liver disease: a curriculum-based review. <b>2018</b> , 9, 170-174		11
660	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 754-763	13.4	55
659	Red blood cell distribution width to platelet ratio levels in assessment of histologic severity in patients with primary biliary cholangitis. <b>2018</b> , 78, 258-263		5
658	Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis. <b>2018</b> , 97, e9843		3
657	Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. <b>2018</b> , 67, 1135-1145		35
656	A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. <b>2018</b> , 36, 144-146		30
655	Animal models of biliary injury and altered bile acid metabolism. <b>2018</b> , 1864, 1254-1261		67
654	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <b>2018</b> , 67, 1890-1902		139
653	Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation. <b>2018</b> , 53, 56-63		12
652	An update on the physiopathology and therapeutic management of cholestatic pruritus in children. <b>2018</b> , 42, 103-109		16

651	Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. <b>2018</b> , 113, 49-55	65
650	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <b>2018</b> , 1864, 1415-1422	2
649	How the biliary tree maintains immune tolerance?. <b>2018</b> , 1864, 1367-1373	8
648	Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma. <b>2018</b> , 1864, 1390-1400	31
647	Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. <b>2018</b> , 38, 399-411	20
646	A novel prognostic model for transplant-free survival in primary sclerosing cholangitis. <b>2018</b> , 67, 1864-1869	41
645	Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity. <b>2018</b> , 50, 68-75	18
644	Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. <b>2018</b> , 11, 11-18	21
643	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <b>2018</b> , 113, 254-264	44
642	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. <b>2018</b> , 67, 2338-2351	56
641	Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis. <b>2018</b> , 38, 1110-1116	5
640	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <b>2018</b> , 67, 1920-1930	35
639	Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study. <b>2018</b> , 31, 590-599	5
638	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <b>2018</b> , 67, 1517-1524	28
637	Plasma exchange for the management of refractory pruritus of cholestasis: A report of three cases and review of literature. <b>2018</b> , 33, 412-418	5
636	Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011. <b>2018</b> , 38, 532-541	42
635	An Argument for Vitamin D, A, and Zinc Monitoring in Cirrhosis. <b>2018</b> , 17, 920-932	12
634	UEG Week 2018 Poster Presentations. <b>2018</b> , 6, A135	14

633	Intrauterine fetal demise. <b>2018</b> , 479-485	
632	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. <b>2018</b> , 110, 641-649	2
631	Current practices and future prospects for the management of gallbladder polyps: A topical review. <b>2018</b> , 24, 2844-2852	38
630	Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. <b>2019</b> , 32, 1-23	25
629	Frequency, Risk Factors, and Outcome of Gallbladder Polyps in Patients With Primary Sclerosing Cholangitis: A Case-Control Study. <b>2018</b> , 2, 1440-1445	12
628	Inhibitory Effect of Ursodeoxycholic Acid on Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. <b>2018</b> , 9, 2849	8
627	Preferred S-adenosylmethionine prescription in routine practice for intrahepatic cholestasis management: results of a multinomial logistic regression grid-optimization approach. <b>2018</b> , Volume 8, 1-9	
626	Primary sclerosing cholangitis leads to dysfunction and loss of MAIT cells. <b>2018</b> , 48, 1997-2004	10
625	Intrahepatic cholestasis of pregnancy: Review of six national and regional guidelines. <b>2018</b> , 231, 180-187	72
624	Autoimmune sclerosing cholangitis: Evidence and open questions. <b>2018</b> , 95, 15-25	18
623	Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. <b>2018</b> , 7,	55
622	Gastrointestinal Manifestations of Systemic Sclerosis. <b>2018</b> , 8,	40
621	Increased prescribing of ursodeoxycholic acid in Norway. <b>2018</b> , 40, 1454-1457	
620	Identification of potential biomarkers in cholestasis and the therapeutic effect of melatonin by metabolomics, multivariate data and pathway analyses. <b>2018</b> , 42, 2515-2526	6
619	Primary sclerosing cholangitis in children versus adults: lessons for the clinic. <b>2018</b> , 12, 1025-1032	7
618	Nutritional issues in patients with obesity and cirrhosis. <b>2018</b> , 24, 3330-3346	36
617	PNPLA3 p.I148M and TM6SF2 p.E167K variants do not predispose to liver injury in cholestatic liver diseases: A prospective analysis of 178 patients with PSC. <b>2018</b> , 13, e0202942	3
616	[IgG4-associated cholangitis - clinical presentation of an overlooked disease entity]. <b>2018</b> , 59, 560-566	0

615	Understanding and Treating Pruritus in Primary Biliary Cholangitis. <b>2018</b> , 22, 517-532	12
614	Role of Bile Acids and the Biliary HCO Umbrella in the Pathogenesis of Primary Biliary Cholangitis. <b>2018</b> , 22, 457-479	16
613	WITHDRAWN: Primary sclerosing cholangitis: A review and update. <b>2018</b> ,	
612	Serological markers of extracellular matrix remodeling predict transplant-free survival in primary sclerosing cholangitis. <b>2018</b> , 48, 179-189	21
611	Endoscopic Management of Hepatobiliary Complications of Inflammatory Bowel Disease. <b>2018</b> , 231-238	
610	Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis. <b>2018</b> , 22, 603-611	9
609	Management and treatment of gallbladder polyps. <b>2018</b> , 150, 487-491	0
608	Clinical guidelines for primary sclerosing cholangitis 2017. <b>2018</b> , 53, 1006-1034	21
607	Emerging therapeutic targets for primary sclerosing cholangitis. <b>2018</b> , 6, 393-401	
606	A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity. <b>2018</b> , 18, 97	5
605	Calcium Signaling in Liver Injury and Regeneration. <b>2018</b> , 5, 192	25
604	Bile Duct Diseases. <b>2018</b> , 515-593	9
603	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <b>2018</b> , 155, 752-759.e5	44
602	Diagnosis accuracy of serum glypican-3 level in patients with hepatocellular carcinoma: a systematic review with meta-analysis. <b>2018</b> , 33, 353-363	8
601	Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance. <b>2018</b> , 9, 609	46
600	Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. <b>2018</b> , 17, 854-865	18
599	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy. <b>2018</b> , 20, 916-924	7
598	Primary Sclerosing Cholangitis. <b>2018</b> , 233-242	

597	Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness. <b>2018</b> , 63, 2547-2554	3
596	Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. <b>2018</b> , 48, 169-178	18
595	A case report of immunoglobulin G4-related sclerosing cholangitis with multiple relapse. <b>2018</b> , 97, e0700	
594	Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. <b>2018</b> , 9, 931	28
593	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. <b>2018</b> , 42, 521-528	21
592	Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 mice and human primary sclerosing cholangitis. <b>2018</b> , 98, 1465-1477	20
591	Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection. <b>2018</b> , 8, 12179	4
590	Primary biliary cholangitis. <b>2018</b> , 151, 242-249	1
589	Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. <b>2018</b> , 13, e0202686	2
588	Autoimmune Hepatitis and Overlap Syndromes. <b>2018</b> , 309-315	
587	Primary Biliary Cholangitis. <b>2018</b> , 409-421	
586	Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment. <b>2018</b> , 30, 1352-1360	4
585	Primary Biliary Cholangitis. <b>2018</b> , 328-340	
584	Sclerosing Cholangitis. <b>2018</b> , 341-354	1
583	Pregnancy and the Liver. <b>2018</b> , 572-587	
582	The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. <b>2018</b> , 38, 2329-2339	12
581	Dominant strictures in primary sclerosing cholangitis: A multicenter survey of clinical definitions and practices. <b>2018</b> , 2, 836-844	17
580	Variant syndromes of primary biliary cholangitis. <b>2018</b> , 34-35, 55-61	5



579	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. <b>2018</b> , 13, e0190005	7
578	Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. <b>2018</b> , 13, e0193929	4
577	Update in the Care and Management of Patients with Primary Sclerosing Cholangitis. <b>2018</b> , 20, 29	3
576	Endoscopic management of primary sclerosing cholangitis. <b>2018</b> , 12, 693-703	7
575	Primärbiliäre Cholangitis in Graz: Präsentation, Verlauf und Outcome. <b>2018</b> , 16, 56-62	0
574	Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). <b>2018</b> , 13, e0193960	11
573	Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers. <b>2019</b> , 8, 70-77	3
572	Fatigue in chronic liver disease: New insights and therapeutic approaches. <b>2019</b> , 39, 6-19	32
571	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 172-193	13.4 305
570	Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. <b>2019</b> , 69, 237-244	13
569	Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: Diagnostic and management implications. <b>2019</b> , 34, 425-435	5
568	An Imaging Biomarker for Assessing Hepatic Function in Patients With Primary Sclerosing Cholangitis. <b>2019</b> , 17, 192-199.e3	12
567	Prospective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis. <b>2019</b> , 29, 818-828	6
566	Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. <b>2019</b> , 9, 11525	24
565	Treatment of Pruritus Secondary to Liver Disease. <b>2019</b> , 21, 48	16
564	Verbesserte Prognose, aber limitierte Therapieoptionen für PBC und PSC. <b>2019</b> , 6, 41-46	
563	Epidemiological survey of antinuclear antibodies in healthy population and analysis of clinical characteristics of positive population. <b>2019</b> , 33, e22965	12
562	The risk of liver cancer in autoimmune liver diseases. <b>2019</b> , 11, 1758835919861914	13

561	Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 992-999	13.4	9
560	Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis. <b>2019</b> , 50, 580-589		36
559	Biliary endoscopy in the management of primary sclerosing cholangitis and its complications. <b>2019</b> , 3, 106-117		11
558	Liver Disease in Pregnancy and Transplant. <b>2019</b> , 21, 43		6
557	[Pruritus in systemic diseases : Common and rare etiologies]. <b>2019</b> , 60, 814-820		2
556	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. <b>2019</b> , 33, 10269-10279		18
555	Pharmacologic management of primary sclerosing cholangitis: what's in the pipeline?. <b>2019</b> , 13, 723-729		5
554	Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up. <b>2019</b> , 39, 1938-1964		18
553	Muscle psoas indices measured by ultrasound in cirrhosis - Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. <b>2019</b> , 51, 1502-1507		13
552	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <b>2019</b> , 54, 1391-1396		3
551	Complications of cholestasis. <b>2019</b> , 47, 818-821		0
550	AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. <b>2019</b> , 17, 2416-2422		31
549	Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study. <b>2019</b> , 126, 1633-1640		18
548	Cholyglycine determination by an automated chemiluminescence immunoassay: preliminary results in the intrahepatic cholestasis of pregnancy. <b>2019</b> , 4, 35-35		
547	Transcriptome Profiling of Placenta through Pregnancy Reveals Dysregulation of Bile Acids Transport and Detoxification Function. <b>2019</b> , 20,		2
546	Stevens-Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. <b>2019</b> , 47, 4537-4543		9
545	Ursodeoxycholic acid in pregnancy?. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1237-1245	13.4	10
544	Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. <b>2019</b> , 54, 984-990		3

543	Clinical profile and outcome of primary sclerosing cholangitis: A single-centre experience from western India. <b>2019</b> , 38, 295-302	6
542	Cholestatic pruritus: Emerging mechanisms and therapeutics. <b>2019</b> , 81, 1371-1378	10
541	Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. <b>2019</b> , 14, 753-761	9
540	[Syphilitic hepatitis. Report of three cases]. <b>2019</b> , 147, 251-255	2
539	Acoustic Radiation Force Impulse (ARFI) Elastography in Autoimmune and Cholestatic Liver Diseases. <b>2019</b> , 18, 23-29	10
538	Rheumatologie und Hepatologie: Diagnostik und Therapie von autoimmunen Lebererkrankungen. <b>2019</b> , 46,	
537	Targeting FXR in Cholestasis. <b>2019</b> , 256, 299-324	34
536	Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis. <b>2019</b> , 39, 2230-2237	6
535	Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. <b>2019</b> , 115, 107-110	14
534	Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. <b>2019</b> , 3, 118-127	4
533	[Hepatobiliary Manifestation of Inflammatory Bowel Disease]. <b>2019</b> , 73, 248-259	0
532	Contributing factors and outcomes of burn-associated cholestasis. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 563-574	9
531	Intrahepatic Cholestasis of Pregnancy as a Clinical Manifestation of Sodium-Taurocholate Cotransporting Polypeptide Deficiency. <b>2019</b> , 248, 57-61	7
530	British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. <b>2019</b> , 68, 1356-1378	73
529	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. <b>2019</b> , 18, 215-219	3
528	Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database. <b>2019</b> , 103, 1191-1198	2
527	Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study. <b>2019</b> , 13, 1492-1500	24
526	Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 573-585	13.4 41

525	Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin. <b>2019</b> , 11, 273-281	3
524	ACR Appropriateness Criteria Jaundice. <b>2019</b> , 16, S126-S140	4
523	Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases. <b>2019</b> , 9, 7190	10
522	Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?. <b>2019</b> , 20,	12
521	Treatment response in primary biliary cholangitis: The role of autoimmune hepatitis features. <b>2019</b> , 18, 488-493	1
520	Magnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions. <b>2019</b> , 39, 369-380	13
519	Association between the concurrence of pre-existing chronic liver disease and worse prognosis in patients with an herb- thunb. induced liver injury: a case-control study from a specialised liver disease center in China. <b>2019</b> , 9, e023567	11
518	[Immune-mediated cholangiopathies : Diagnostic and therapeutic challenges]. <b>2019</b> , 59, 348-356	
517	Mechanisms and in vitro models of drug-induced cholestasis. <b>2019</b> , 93, 1169-1186	16
516	Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. <b>2019</b> , 17, 1372-1378	9
515	Rate of Spleen Length Progression Is a Marker of Outcome in Patients With Primary Sclerosing Cholangitis. <b>2019</b> , 17, 2613-2615	4
514	European S2k Guideline on Chronic Pruritus. <b>2019</b> , 99, 469-506	67
513	Histologically proven AMA positive primary biliary cholangitis but normal serum alkaline phosphatase: Is alkaline phosphatase truly a surrogate marker?. <b>2019</b> , 99, 33-38	21
512	Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management. <b>2019</b> , 64, 632-642	13
511	Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis. <b>2019</b> , 70, 2035-2046	55
510	A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis. <b>2019</b> , 3, 365-381	30
509	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. <b>2019</b> , 209, 22-38	18
508	Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis. <b>2019</b> , 13, 307-317	47

507	Liver Biopsy. <b>2019</b> , 395-407	
506	Pregnancy and Liver Disease. <b>2019</b> , 408-424	
505	Primary Biliary Cholangitis (Formerly Primary Biliary Cirrhosis). <b>2019</b> , 574-591	0
504	Primary Sclerosing Cholangitis. <b>2019</b> , 602-618	
503	Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis. <b>2019</b> , 39, 291-298	7
502	Future Medical Treatment of PSC. <b>2019</b> , 18, 96-106	5
501	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. <b>2019</b> , 49, e13088	7
500	Liver stiffness measurement by acoustic radiation forced impulse and transient elastography in patients with intrahepatic cholestasis. <b>2019</b> , 31, 520-527	5
499	Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. <b>2019</b> , 6, ofz469	3
498	Evolving liver inflammation in biochemically normal individuals with anti-mitochondria antibodies. <b>2019</b> , 10, 10	3
497	Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) Annual Scientific Meeting Abstracts, 11-13 October 2019, Melbourne, Australia. <b>2019</b> , 12, 3-57	4
496	Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. <b>2019</b> , 10, e00020	16
495	Assessment of cholestasis in drug-induced liver injury by different methods. <b>2019</b> , 98, e14399	3
494	Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. <b>2019</b> , 30, 235-243	24
493	Extrapulmonary sarcoidosis primarily presenting as cholestatic liver disease. <b>2019</b> , 12,	1
492	Intrahepatic cystic biliary dilatation constitutes a significant prognostic factor in patients with primary sclerosing cholangitis. <b>2019</b> , 29, 1460-1468	3
491	Cholangiocyte death in ductopenic cholestatic cholangiopathies: Mechanistic basis and emerging therapeutic strategies. <b>2019</b> , 218, 324-339	8
490	Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 483-493	13.4 77

489	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 941-953	13.4	13
488	Unique patterns of glycosylation in immunoglobulin subclass G4-related disease and primary sclerosing cholangitis. <b>2019</b> , 34, 1878-1886		19
487	Basal PPAR $\alpha$ inhibits bile acid metabolism adaptation in chronic cholestatic model induced by $\alpha$ -naphthylisothiocyanate. <b>2019</b> , 300, 31-39		0
486	Is It Necessary to Perform the Pharmacological Interventions for Intrahepatic Cholestasis of Pregnancy? A Bayesian Network Meta-Analysis. <b>2019</b> , 39, 15-26		9
485	Clinical Epidemiology of Chronic Liver Diseases. <b>2019</b> ,		1
484	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <b>2019</b> , 70, 547-562		54
483	Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. <b>2019</b> , 39, 382-388		8
482	Autoimmune Hepatitis and Immune-Mediated Cholestatic Liver Diseases. <b>2019</b> , 251-305		
481	Defective spleen function in autoimmune gastrointestinal disorders. <b>2020</b> , 15, 225-229		11
480	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. <b>2020</b> , 69, 92-102		62
479	TianJiu therapy for $\alpha$ -naphthyl isothiocyanate-induced intrahepatic cholestasis in rats treated with fresh <i>Ranunculus sceleratus</i> L. <b>2020</b> , 248, 112310		3
478	Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. <b>2020</b> , 725, 144167		9
477	Alterations of the bile microbiome in primary sclerosing cholangitis. <b>2020</b> , 69, 665-672		41
476	Drug Therapies for Chronic Cholestatic Liver Diseases. <b>2020</b> , 60, 503-527		16
475	Peribiliary glands: development, dysfunction, related conditions and imaging findings. <b>2020</b> , 45, 416-436		9
474	Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2. <b>2020</b> , 40, 141-154		13
473	Reply to: "UDCA therapy in intrahepatic cholestasis of pregnancy?". <i>Journal of Hepatology</i> , <b>2020</b> , 72, 587-588		2
472	Role of sphingolipids in the pathogenesis of intrahepatic cholestasis. <b>2020</b> , 147, 106399		2

471	Evaluation of the United Kingdom-primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population. <b>2020</b> , 4, 132-139	2
470	Identification of Marker Genes and Pathways in Patients with Primary Biliary Cholangitis. <b>2020</b> , 27, 923-933	1
469	Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <b>2020</b> , 55, 74-81	18
468	Vitamin D-related immunomodulation in patients with liver cirrhosis. <b>2020</b> , 32, 867-876	8
467	Primary biliary cholangitis: pathogenesis and therapeutic opportunities. <b>2020</b> , 17, 93-110	58
466	Chronic Liver Disease in the Obstetric Patient. <b>2020</b> , 63, 193-210	0
465	Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps. <b>2020</b> , 40, 382-392	7
464	Phototherapy for Itch. <b>2020</b> , 38, 145-155	7
463	Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. <b>2020</b> , 51, 90-109	10
462	Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. <b>2020</b> , 72, 671-722	198
461	Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. <b>2020</b> , 1866, 165958	4
460	Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. <b>2020</b> , 95, 2263-2279	7
459	Protocolo diagnóstico de la colestasis. <b>2020</b> , 13, 517-520	
458	Intrahepatic cholestasis of pregnancy: Is a screening for differential diagnoses necessary?. <b>2020</b> , 49, 101907	4
457	Characterization of gut-homing molecules in non-endstage livers of patients with primary sclerosing cholangitis and inflammatory bowel disease. <b>2020</b> , 3, 100054	1
456	Mechanism of Hydrophobic Bile Acid-Induced Hepatocyte Injury and Drug Discovery. <b>2020</b> , 11, 1084	5
455	Cholestasis: The Close Relationship between Bile Acids and Coenzyme Q10. <b>2020</b> ,	
454	An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. <b>2020</b> , 14, 985-998	3

453	Liver involvement in rheumatic diseases. <b>2020</b> , 58, 289-296	2
452	Current laboratory and clinical practices in reporting and interpreting anti-nuclear antibody indirect immunofluorescence (ANA IIF) patterns: results of an international survey. <b>2020</b> , 11, 17	4
451	Enzymatic methods may underestimate the total serum bile acid concentration. <b>2020</b> , 15, e0236372	2
450	Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. <b>2020</b> , 7, CD000493	13
449	Quantitative assessment of disease severity of primary sclerosing cholangitis with T1 mapping and extracellular volume imaging. <b>2021</b> , 46, 2433-2443	2
448	Systemic sclerosis and gastrointestinal involvement. <b>2020</b> , 27, 44-54	0
447	Diseases of the Gallbladder. <b>2020</b> ,	
446	A case of gastric cardia telangiectasias and primary biliary cirrhosis with hemorrhage. <b>2020</b> , 8, 2377-2381	
445	Understanding Fatigue in Primary Biliary Cholangitis. <b>2021</b> , 66, 2380-2386	4
444	Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis. <b>2020</b> , 40, 2744-2757	5
443	A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis. <b>2020</b> , 34, e23501	4
442	Carriers of ABCB4 gene variants show a mild clinical course, but impaired quality of life and limited risk for cholangiocarcinoma. <b>2020</b> , 40, 3042-3050	3
441	Cholestasis Differentially Affects Liver Connexins. <b>2020</b> , 21,	1
440	[Diagnostics and Treatment of indeterminate Biliary Stenoses]. <b>2020</b> , 145, 306-312	0
439	Profiling of the pattern of the human TRB/IGH-CDR3 repertoire in primary biliary cholangitis patients. <b>2020</b> , 83, 106393	2
438	Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation. <b>2020</b> , 34, 8402-8415	8
437	Primary Sclerosing Cholangitis: Burden of Disease and Mortality Using Data from the National Rare Diseases Registry in Italy. <b>2020</b> , 17,	5
436	PSC and Overlap Syndromes. <b>2020</b> , 19, 106-118	1



- 435 Total bile acid to platelet ratio: A noninvasive index for predicting liver fibrosis in primary biliary cholangitis. **2020**, 99, e20502
- 434 A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. **2020**, 51, 1417-1428 20
- 433 Clinical features and MRI progression of small duct primary sclerosing cholangitis (PSC). **2020**, 129, 109101 9
- 432 Tissue engineering of the biliary tract and modelling of cholestatic disorders. *Journal of Hepatology*, **2020**, 73, 918-932 13.4 5
- 431 Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. **2020**, 35, 261-274 14
- 430 Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. **2020**, 40, 1812-1822 17
- 429 European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations. **2020**, 8, 637-666 39
- 428 Diagnosis and Management of Autoimmune Hepatitis. **2020**,
- 427 Quality of Life in Patients with Primary Biliary Cholangitis: A Single-Center Experience in Serbia. **2020**, 38, 515-521 2
- 426 Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis. **2020**, 9, 34
- 425 Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. **2020**, 8, 462-471 4
- 424 Changes in the gut microbiota of mice orally exposed to methylimidazolium ionic liquids. **2020**, 15, e0229745 6
- 423 [Autoimmune mediated cholestatic liver diseases]. **2020**, 145, 296-305 1
- 422 Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. **2020**, 30, 3735-3747<sup>5</sup>
- 421 Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis. **2020**, 26, 1477-1491 7
- 420 Odevixibat and partial external biliary diversion showed equal improvement of cholestasis in a patient with progressive familial intrahepatic cholestasis. **2020**, 13, 6
- 419 Liver disease in pregnancy. **2020**, 50, 1015-1023 10
- 418 Challenging biliary strictures: pathophysiological features, differential diagnosis, diagnostic algorithms, and new clinically relevant biomarkers - part 1. **2020**, 13, 1756284820927292 10

417	Bile Acid Metabolism in Health and Disease. <b>2020</b> , 269-285	1
416	Nutrition in Cholestatic Liver Disease. <b>2020</b> , 19, 1-6	1
415	Making Sense of Overlap and Crossover Syndromes. <b>2020</b> , 263-275	
414	Primary Sclerosing Cholangitis With Features of Autoimmune Hepatitis: Exploring the Global Variation in Management. <b>2020</b> , 4, 399-408	1
413	Inter-reader agreement of interpretation of radiological course of bile duct changes between serial follow-up magnetic resonance imaging/3D magnetic resonance cholangiopancreatography of patients with primary sclerosing cholangitis. <b>2020</b> , 55, 228-235	4
412	Therapies in Inflammatory Bowel Disease Patients with Extraintestinal Manifestations. <b>2020</b> , 101 Suppl 1, 83-97	10
411	Relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study. <b>2020</b> , 55, 216-221	1
410	Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. <b>2020</b> , 99, e19248	4
409	Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC). <b>2020</b> , 72, 1310	15
408	HGF induces protective effects in $\alpha$ -naphthylisothiocyanate-induced intrahepatic cholestasis by counteracting oxidative stress. <b>2020</b> , 174, 113812	6
407	Enhanced expression of miR-21 and miR-150 is a feature of anti-mitochondrial antibody-negative primary biliary cholangitis. <b>2020</b> , 26, 8	1
406	Effectiveness of ursodeoxycholic acid therapy in intrahepatic cholestasis of pregnancy. <b>2020</b> , 9, 1069	
405	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. <b>2020</b> , 55, 588-614	22
404	Mammalian Target of Rapamycin Complex 2 Signaling Is Required for Liver Regeneration in a Cholestatic Liver Injury Murine Model. <b>2020</b> , 190, 1414-1426	3
403	Genetic variants of UDP-glucuronosyltransferase 1A genes are associated with disease presentation and outcome in primary sclerosing cholangitis. <b>2020</b> , 40, 1645-1654	1
402	Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease. <b>2020</b> , 19, 86-95	3
401	Effect of vitamin K1 on survival of patients with chronic liver failure: A retrospective cohort study. <b>2020</b> , 99, e19619	1
400	Benign Recurrent Intrahepatic Cholestasis (BRIC): An African Case Report. <b>2020</b> , 2020, 2894293	5

399	Primary biliary cirrhosis--autoimmune hepatitis overlap syndrome associated with dermatomyositis, autoimmune thyroiditis and antiphospholipid syndrome. <b>2015</b> , 24, 101-4		11
398	Use of Butorphanol as Treatment for Cholestatic Itch. <b>2021</b> , 66, 1693-1699		3
397	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 312-320	13.4	6
396	Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. <b>2021</b> , 31, 2482-2489		2
395	Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. <b>2021</b> , 160, 734-743.e6		25
394	Structure and Function of Hepatobiliary ATP Binding Cassette Transporters. <b>2021</b> , 121, 5240-5288		9
393	Recent advances in the treatment of primary sclerosing cholangitis. <b>2021</b> , 15, 413-425		1
392	Metabolomics analysis delineates the therapeutic effects of Huangqi decoction and astragalosides on <i>Ehaphthylisothiocyanate</i> (ANIT) -induced cholestasis in rats. <b>2021</b> , 268, 113658		4
391	Dehydrodiconiferyl alcohol, a lignan from <i>Herpetospermum pedunculatum</i> , alleviates cholestasis by activating pathways associated with the farnesoid X receptor. <b>2021</b> , 80, 153378		6
390	Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis. <b>2021</b> , 183, 114312		4
389	Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. <b>2021</b> , 3, 100178		1
388	Management of gallbladder polyps. <b>2021</b> , 53, 119-123		1
387	Gadoxetic acid-enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression. <b>2021</b> , 46, 979-991		2
386	Intrahepatic Cholestasis of Pregnancy: Natural History and Current Management. <b>2021</b> , 41, 103-108		2
385	Cholangiocarcinoma Surveillance in Primary Sclerosing Cholangitis and IgG4-Related Sclerosing Cholangitis. <b>2021</b> , 435-448		
384	Microenvironment Activatable Nanoprodrug Based on Gripper-like Cyclic Phenylboronic Acid to Precisely and Effectively Alleviate Drug-induced Hepatitis. <b>2021</b> , 11, 8301-8321		0
383	Primary Sclerosing Cholangitis. <b>2021</b> , 135-152		
382	Isolated Type Immunoglobulin G4 Sclerosing Cholangitis: The Misdiagnosed Cholangiocarcinoma. <b>2021</b> , 13, 75-81		1

- 381 73-Year-Old Male with Diffuse, Itchy Skin. **2021**, 97-101
- 380 Gallbladder polyps: evolving approach to the diagnosis and management. **2021**, 38, 1-9 5
- 379 Overlap Syndromes. **2021**, 169-191
- 378 Drug-Induced Cholangiopathies. **2021**, 211-227
- 377 PSC-Associated Cholangiocarcinoma: Diagnostic and Therapeutic Considerations. **2021**, 251-264
- 376 The evolving potential of precision medicine in the management of autoimmune liver disease. **2021**, 135-167 1
- 375 Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis. **2021**, 81, 116-120
- 374 Behandlung progressiv-familiärer intrahepatischer Cholestasen (PFIC). **2021**, 356-361
- 373 Pregnancy-related liver pathology: hyperemesis gravidarum, cholestatic hepatitis of pregnancy, preeclampsia/eclampsia, HELLP-syndrome, acute fatty liver of pregnancy. 1, 7-16
- 372 Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. **2021**, 9, 53-66
- 371 Rodent models of cholestatic liver disease: A practical guide for translational research. **2021**, 41, 656-682 4
- 370 Primary biliary cholangitis-autoimmune hepatitis overlap syndrome: Case report and literature review. **2021**, 9, 1647-1650
- 369 Diagnostic and conservative treatment nuances in patients with obstructive jaundice: in the wake of Russian consensus. **2021**, 93, 138-144
- 368 Mitochondrial Dysfunction and Oxidative Stress in Liver Transplantation and Underlying Diseases: New Insights and Therapeutics. **2021**, 105, 2362-2373 4
- 367 Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study. **2021**, 30, 886-894 5
- 366 ABCB4-alteration screening in adult-onset cholestasis. **2021**, 53, 261-262
- 365 Risk factors for recurrent primary biliary cirrhosis after liver transplantation: A systematic review and meta-analysis. **2021**, 53, 309-317 1
- 364 Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis. **2021**, 12, 649376 0

363	Predictive Model of Ursodeoxycholic Acid Treatment Response in Primary Biliary Cholangitis. <b>2021</b> , 9, 187-193	0
362	Expanded circulating peripheral helper T cells in primary biliary cholangitis: Tph cells in PBC. <b>2021</b> , 131, 44-50	1
361	Cholestasis-Associated Pruritus and Its Pruritogens. <b>2021</b> , 8, 639674	4
360	Exome sequencing in patient-parent trios suggests new candidate genes for early-onset primary sclerosing cholangitis. <b>2021</b> , 41, 1044-1057	1
359	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <b>2021</b> , 12, e00315	4
358	Is it time for recommendations to reflect reality in PSC surveillance?. <b>2022</b> , 13, 88-89	
357	Analysis of Autoantibodies against Promyelocytic Leukemia Nuclear Body Components and Biochemical Parameters in Sera of Patients with Primary Biliary Cholangitis. <b>2021</b> , 11,	3
356	Safety of fibrates in cholestatic liver diseases. <b>2021</b> , 41, 1335-1343	2
355	Maladies cholestatiques de l'adulte : cholangite biliaire primitive et cholangite sclérosante primitive. <b>2021</b> , 32, 21-22	
354	Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan. <b>2021</b> , 15, 437-443	1
353	Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. <b>2021</b> , 128, 1635-1644	4
352	Biomarkers of cholestasis. <b>2021</b> , 15, 437-454	2
351	Primary sclerosing cholangitis. <b>2021</b> , 6, 29	4
350	Salivary Biomarkers and Oral Health in Liver Transplant Recipients, with an Emphasis on Diabetes. <b>2021</b> , 11,	2
349	Antibiotic-associated drug-induced liver damage with cholestasis: actualization of problem in COVID-19 era. <b>2021</b> , 31-43	3
348	[Intrahepatic cholestasis of pregnancy]. <b>2021</b> , 54, 1-16	0
347	Hepatic Manifestations of Inflammatory Bowel Disease. <b>2021</b> , 17, 292-296	0
346	Diagnostic value of magnetic resonance parametric mapping for non-invasive assessment of liver fibrosis in patients with primary sclerosing cholangitis. <b>2021</b> , 21, 65	2

345	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. <b>2021</b> , 160, 1784-1798.e0	17
344	MicroRNA-34a Promotes EMT and Liver Fibrosis in Primary Biliary Cholangitis by Regulating TGF-1/smad Pathway. <b>2021</b> , 2021, 6890423	3
343	Chronic Fatigue Persists in a Significant Proportion of Female Patients After Transplantation for Primary Sclerosing Cholangitis. <b>2021</b> , 27, 1032-1040	2
342	S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis. <b>2021</b> , 27, 1973-1992	2
341	Protective Functions of ZO-2/Tjp2 Expressed in Hepatocytes and Cholangiocytes Against Liver Injury and Cholestasis. <b>2021</b> , 160, 2103-2118	6
340	Predictive factors associated with disease recurrence in patients with severe intrahepatic cholestasis of pregnancy: a retrospective study of 118 cases. <b>2021</b> , 1-8	
339	Diagnostic potential of endoscopic ultrasound for inflammatory bowel diseases and their complications. <b>2021</b> , 176-184	
338	Spatial heterogeneity of hepatic fibrosis in primary sclerosing cholangitis vs. viral hepatitis assessed by MR elastography. <b>2021</b> , 11, 9820	1
337	Treatment of primary sclerosing cholangitis. <b>2021</b> , 53, 1531-1538	1
336	Fibrotic Events in the Progression of Cholestatic Liver Disease. <b>2021</b> , 10,	4
335	The many facets of bile acids in the physiology and pathophysiology of the human liver. <b>2021</b> , 402, 1047-1062	2
334	Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. <b>2021</b> , 16, 41	1
333	Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. <b>2021</b> ,	1
332	Autoimmune liver damage in patients with primary Sjogren's syndrome associated with anticentromeric antibodies. <b>2021</b> , 15, 27-34	
331	Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. <b>2021</b> , 3, 100286	7
330	Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. <b>2021</b> , 3, 100255	11
329	SYMPTOMATIC CHOLELITHIASIS AS THE PRESENTATION OF PEDIATRIC PRIMARY SCLEROSING CHOLANGITIS - CASE SERIES AND LITERATURE REVIEW. <b>2021</b> , 58, 227-233	0
328	Letter to the editor: Both simplified and revised IAIHG scores should be considered in diagnosing acute autoimmune hepatitis. <b>2021</b> , 41, 1973-1975	

327	Role of bile acids in liver diseases mediated by the gut microbiome. <b>2021</b> , 27, 3010-3021	1
326	Non-invasive diagnosis and follow-up of primary sclerosing cholangitis. <b>2021</b> , 46, 101775	0
325	Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Age Related Macular Degeneration, Role in Pathophysiology, and Possible New Therapeutic Strategies. <b>2021</b> , 10,	2
324	Primary sclerosing cholangitis with moderately elevated serum-IgG4 - characterization and outcome of a distinct variant phenotype. <b>2021</b> ,	0
323	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <b>2021</b> , 51, 725-749	14
322	Common ABCB4 and ABCB11 genotypes are associated with idiopathic chronic cholestasis in adults. <b>2021</b> ,	0
321	Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis. <b>2021</b> , 41, 2681-2692	1
320	Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice. <b>2021</b> ,	1
319	Sclerosing Cholangitis in Pediatric Inflammatory Bowel Disease: Early Diagnosis and Management Affect Clinical Outcome. <b>2021</b> , 238, 50-56.e3	2
318	Non-invasive diagnosis and follow-up of primary biliary cholangitis. <b>2021</b> , 46, 101770	1
317	The Role of Vitamin K in Cholestatic Liver Disease. <b>2021</b> , 13,	2
316	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <b>2021</b> , 56, 593-619	27
315	Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. <b>2021</b> , 41, 2404-2417	7
314	Geriatric poplasyonda kolestatik karaciğer hastalıklarında etiyoloji ve tanşal yaklař: 185 vakalık tek merkez deneyimi. 1-5	
313	Effect of transient obstructive cholestasis on liver histology: a cross-sectional study. <b>2021</b> , 139, 351-363	0
312	Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. <b>2021</b> , 53, 1020-1027	0
311	Synthesis of ursodeoxycholic acid by electrochemical stereoselective reduction of 7-ketolithocholic acid in aprotic solvents. <b>2021</b> , 11, 16273	0
310	Management of Intrahepatic Cholestasis of Pregnancy: Recommendations of the Working Group on Obstetrics and Prenatal Medicine - Section on Maternal Disorders. <b>2021</b> , 81, 922-939	1

309	Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-based Studies. <b>2021</b> ,	1
308	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <b>2021</b> , 161, 1764-1775.e5	0
307	Intrahepatic Cholestasis of Pregnancy. <b>2021</b> , 81, 940-947	1
306	Predicting Target Genes of San-Huang-Chai-Zhu Formula in Treating ANIT-Induced Acute Intrahepatic Cholestasis Rat Model via Bioinformatics Analysis Combined with Experimental Validation. <b>2021</b> , 2021, 5320445	0
305	Outcome of pregnancy in patients with primary sclerosing cholangitis. <b>2021</b> ,	0
304	Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. <b>2021</b> ,	2
303	Assessment of prognostic value and interreader agreement of ANALI scores in patients with primary sclerosing cholangitis. <b>2021</b> , 142, 109884	0
302	Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up. <b>2021</b> , 54, 1202-1212	1
301	Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study. <b>2021</b> , 45, 101751	11
300	Odevixibat: First Approval. <b>2021</b> , 81, 1781-1786	12
299	Systemic causes of non-dermatologic chronic pruritus in the pediatric population and their management: An unexplored area. <b>2021</b> , 38, 1051-1060	0
298	Modern imaging of cholangitis. <b>2021</b> , 94, 20210417	1
297	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. <b>2021</b> , 3, 100328	1
296	Advances of natural activators for Nrf2 signaling pathway on cholestatic liver injury protection: a review. <b>2021</b> , 910, 174447	1
295	Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. <b>2021</b> , 14, 17562848211002023	3
294	Gastrointestinal and Nutritional Disorders. <b>2021</b> , 1-31	
293	The Role of Autoantibodies in the Diagnosis of Autoimmune Liver Disease: Lessons Learned from Clinical Practice.. <b>2022</b> , 7, 259-267	2
292	Etiology and Pathogenesis of Gall Bladder Cancer. <b>2021</b> , 35-55	0



291	Pregnancy and Diseases of the Biliary Tree. <b>2021</b> , 263-280	
290	Primärsklerosierende Cholangitis. <b>2021</b> , 377-382	
289	Biliary System. <b>2021</b> , 583-620	
288	Gallstones. 1808-1834	5
287	Update on primary sclerosing cholangitis. <b>2017</b> , 9, 107-110	4
286	Chronic Conditions and Cancer at the End of Life. <b>2016</b> , 455-475	1
285	Management of primary sclerosing cholangitis and its complications: an algorithmic approach. <b>2021</b> , 15, 6-20	4
284	The Liver in Pregnancy. <b>2018</b> , 817-836.e5	0
283	Primary Sclerosing Cholangitis. <b>2012</b> , 754-781	4
282	The effect of liver test abnormalities on the prognosis of COVID-19. <b>2020</b> , 19, 614-621	22
281	IgG4/IgG RNA ratio does not accurately discriminate IgG4-related disease from pancreatobiliary cancer. <b>2020</b> , 2, 100116	3
280	Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. <b>2021</b> , 53, 302-313	5
279	Pregnancy and ABCB4 gene mutation: risk of recurrent cholelithiasis. <b>2015</b> , 2015,	1
278	Increased cholestatic enzymes in two patients with long-term history of ulcerative colitis: consider primary biliary cholangitis not always primary sclerosing cholangitis. <b>2017</b> , 2017,	2
277	The TGR5 receptor mediates bile acid-induced itch and analgesia. <b>2013</b> , 123, 1513-30	229
276	Atypical Presentation of Adrenocortical Insufficiency with Anorexia and Jaundice. <b>2018</b> , 19, 705-709	2
275	Cholestatic liver diseases: An era of emerging therapies. <b>2019</b> , 7, 1571-1581	8
274	Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholerisis in the normal rat. <b>2011</b> , 6, e28717	28

273	AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. <b>2016</b> , 11, e0160525	9
272	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. <b>2016</b> , 11, e0164224	28
271	Analytical evaluation of three enzymatic assays for measuring total bile acids in plasma using a fully-automated clinical chemistry platform. <b>2017</b> , 12, e0179200	18
270	Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective. <b>2014</b> , 2, 266-84	16
269	[Russian consensus on current issues in the diagnosis and treatment of obstructive jaundice syndrome]. <b>2020</b> , 5-17	9
268	Detection of anti-kelch-like 12 and anti-hexokinase 1 antibodies in primary biliary cholangitis patients in China. <b>2021</b> , 113, 585-590	1
267	Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. <b>2019</b> , 32, 124-133	22
266	Gallbladder cancer: epidemiology and outcome. <b>2014</b> , 6, 99-109	483
265	Management of primary biliary cholangitis prior to obeticholic acid availability. <b>2018</b> , 109, 410-417	5
264	Variety of lung involvement in autoimmune liver diseases. <b>2018</b> , 90, 107-112	1
263	Medicinal liver damage in adults. <b>2020</b> , 174, 29-54	13
262	Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial. <b>2018</b> , 5, 1-78	6
261	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. <b>2015</b> , 19, 1-409, v-vi	101
260	Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes. <b>2015</b> , 21, 150-7	10
259	Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. <b>2016</b> , 22, 350-358	1
258	Bile acids, nuclear receptors and cytochrome P450. <b>2016</b> , 65, S427-S440	16
257	Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. <b>2012</b> , 18, 1-15	98
256	Clinical management of inflammatory bowel disease in the organ recipient. <b>2014</b> , 20, 3525-33	22

255	Overlap syndrome consisting of PSC-AIH with concomitant presence of a membranous glomerulonephritis and ulcerative colitis. <b>2014</b> , 20, 4811-6	6
254	Atypical causes of cholestasis. <b>2014</b> , 20, 9418-26	50
253	Prognostic value of neutrophil distribution in cholangiocarcinoma. <b>2015</b> , 21, 4961-8	16
252	Autoimmune hepatitis-primary biliary cirrhosis concurrent with biliary stricture after liver transplantation. <b>2015</b> , 21, 2236-41	4
251	Clinical characteristics of drug-induced liver injury and primary biliary cirrhosis. <b>2016</b> , 22, 7579-86	7
250	Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. <b>2016</b> , 22, 8187-93	27
249	Inflammatory bowel disease in liver transplanted patients. <b>2017</b> , 23, 3214-3227	6
248	Recent advances in the management of pruritus in chronic liver diseases. <b>2017</b> , 23, 3418-3426	20
247	Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. <b>2017</b> , 23, 4839-4846	15
246	Serum amyloid A levels in patients with liver diseases. <b>2019</b> , 25, 6440-6450	10
245	Evolving role of magnetic resonance techniques in primary sclerosing cholangitis. <b>2019</b> , 25, 644-658	5
244	Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. <b>2019</b> , 25, 659-671	44
243	Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. <b>2020</b> , 26, 3542-3561	10
242	Autoimmune liver disease and the enteric microbiome. <b>2018</b> , 4, 334-346	1
241	A Review of Extraintestinal Manifestations and Complications of Inflammatory Bowel Disease. <b>2019</b> , 7, 66-73	16
240	Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review. <b>2020</b> , 12, 46-63	8
239	Geoepidemiologic variation in outcomes of primary sclerosing cholangitis. <b>2020</b> , 12, 116-124	2
238	Vitamin D deficiency in chronic liver disease. <b>2014</b> , 6, 901-15	63

- 237 Immune-mediated bile duct injury: The case of primary biliary cirrhosis. **2010**, 1, 118-28 3
- 236 The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis. **2015**, 15, e25539 9
- 235 Clinical Course and Genetic Susceptibility of Primary Biliary Cirrhosis: Analysis of a Prospective Cohort. **2016**, 16, e31681 3
- 234 Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. **2021**, 13, 1336-1366 0
- 233 NSAID-induced liver damage with cholestasis. **2021**, 37-48
- 232 10 Cholestatistische leverziekten. **2009**, 100-107
- 231 [Prognosis of Korean patients with primary biliary cirrhosis]. **2010**, 16, 109-11
- 230 Primary Biliary Cirrhosis. **2011**, 725-739
- 229 Autres infections virales et grossesse. **2011**, 361-372
- 228 Managing the Patient with Features of Overlapping Autoimmune Liver Disease. **2012**, 217-234
- 227 A Case of Cholangiocarcinoma and Colorectal Cancer Diagnosed Simultaneously in a Patient with Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis. **2012**, 10, 392 1
- 226 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 225 Primary sclerosing cholangitis. **2012**, 208-218
- 224 Primary biliary cirrhosis and liver transplantation. **2012**, 1, 66-80 8
- 223 Suppression of Inflammatory Mucosal Milieu by Administration of Regulatory Dendritic Cells in an Animal Model of Primary Biliary Cirrhosis. **2012**, 2, 30-34
- 222 Maternale Erkrankungen in der Schwangerschaft. **2012**, 369-674
- 221 Primary Biliary Cirrhosis. **2012**, 738-753 4
- 220 Is there Still a Role for Ursodeoxycholic Acid Treatment in Patients with Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis?. 156-158

219 Monitoring the Patient Awaiting Liver Transplantation. 13-25

218 Cholestatic and Autoimmune Liver Disease. 110-120

217 A study of the effects of saliva stimulation by nizatidine on dry mouth symptoms of primary biliary cirrhosis. **2013**, 5, 90-6

216 Lipids | Bile Salts. **2013**, 739-743

215 Primary Biliary Cirrhosis. **2014**, 253-279

214 Overlap Syndromes. **2014**, 317-329

213 Primary Sclerosing Cholangitis (PSC). **2014**, 301-316

212 The Geoepidemiology of Autoimmune Liver Disease. **2014**, 27-43

211 Diagnostic Liver Immunology. **2014**, 45-53

210 Complications of Cholestasis. **2014**, 163-188

209 Leber, Galle und Pankreas. **2014**, 145-186

208 Medical Therapy of Hepatobiliary Diseases Associated with Ulcerative Colitis. **2014**, 439-456

207 Diagnosis and UDCA Treatment of Primary Biliary Cirrhosis. **2014**, 249-259

206 Management of the Patients with Feature of Autoimmune Hepatitis. **2014**, 277-286

205 New Histological Staging and Grading System for Primary Biliary Cirrhosis. **2014**, 215-232

204 IgG4 Related Cholangitis. **2014**, 87-110

203 Oxycodon for pruritus in jaundice due to hepatocellular carcinoma. **2014**, 9, 510-513

202 Diagnosis and Treatment: ERCP in PSC. **2015**, 309-322

201 Arzneimitteltherapiesicherheit und besondere Verfahren. **2015**, 863-966

200 Prim sklerosierende Cholangitis. **2015**, 1-8

199 Sekund sklerosierende Cholangitis. **2015**, 1-7

198 Indications for Liver Transplantation. **2015**, 97-125

197 Leberzirrhose und ihre Komplikationen. **2015**, 1-9

196 Primary Sclerosing Cholangitis. **2015**, 43-59

195 Hepatobiliary Diseases. **2016**, 253-266

194 Leberzirrhose und ihre Komplikationen. **2016**, 259-266

193 sekund sklerosierende Cholangitis. **2016**, 221-226

192 sekund sklerosierende Cholangitis. **2016**, 221-226

191 Leberzirrhose und ihre Komplikationen. **2016**, 259-266

190 Assessment of Bile Duct Tumors: Endoscopic vs Radiographic. **2016**, 329-339

2

189 Future Therapies for Primary Sclerosing Cholangitis. **2017**, 153-166

188 Liver Transplantation for PSC. **2017**, 203-209

187 IgG4-Related Sclerosing Cholangitis. **2017**, 59-72

186 Ursodeoxycholic Acid Treatment in Primary Sclerosing Cholangitis. **2017**, 145-152

4

185 Primary Biliary Cholangitis. **2017**, 227-242

184 Primary Sclerosing Cholangitis. **2017**, 243-259

- 183 Miscellaneous Disorders: Pregnancy-Associated Liver Disorders, Vascular Disorders, Granulomatous Diseases, and Amyloidosis. **2017**, 405-451
- 182 Review of Pathophysiological Aspects and Risk Factors for Liver Dysfunction. 069-076
- 181 A contribution to the differential diagnostics of sclerosing cholangitides. **2017**, 63, 50-55 1
- 180 Non-invasive methods for diagnostics of liver fibrosis in patients with autoimmune hepatitis and autoimmune hepatitis - primary biliary cirrhosis. **2017**, 94, 843-850
- 179 A Case of Fetal Cholelithiasis Related to Maternal Intrahepatic Cholestasis of Pregnancy. **2017**, 24, 92
- 178 Pathologies des canaux biliaires. **2017**, 191-213
- 177 Liver Disease in Pediatric Inflammatory Bowel Disease. **2017**, 117-134
- 176 Bile Acids and Cholestatic Liver Disease 1: Primary Biliary Cholangitis (PBC). **2017**, 109-119
- 175 A New Mutation Causing Progressive Familial Intrahepatic Cholestasis Type 3 in Association with Autoimmune Hepatitis. **2017**, 4, 000537 1
- 174 Drug-Induced Liver Disease. **2017**,
- 173 Acute hepatitis B virus infection and severe non-immune haemolytic anaemia: a rare relationship. **2017**, 2017, 1
- 172 Determination of Some Phyto-constituents Present in Terminalia catappa Endocarp Flour and Biochemical Evaluation of its Ethanolic Extract on Hepatic Indices in Male Wistar Rats. **2017**, 13, 27-36 1
- 171 Primary and Secondary Sclerosing Cholangitis. **2018**, 626-647.e6
- 170 Molecular and Genetics-Based Diagnostics. **2018**, 127-135.e2
- 169 Leber. **2018**, 321-451
- 168 Primary Biliary Cholangitis. **2018**, 610-625.e3
- 167 PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis. **2018**, 64, 659-664 1
- 166 Primer biliyer kolanjit hastalarında tiroid otoimmünitesinin değerlendirilmesi.

- 165 Primary Sclerosing Cholangitis Overlapping with IBD. **2019**, 191-204
- 164 Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018). **2019**, 91, 9-15 1
- 163 Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases.
- 162 Biomarcadores em Hepatologia. **2019**, 18-23
- 161 Cholestasis syndrome in a comorbid patient: diagnostic difficulties. **2019**, 73-79
- 160 THE USE OF HERBAL REMEDIES IN THE TREATMENT OF HEPATOBILIARY DISEASES: TRENDS AND PROSPECTS. **2019**, 12, 42-62
- 159 Protective functions of ZO-2/Tjp2 expressed in hepatocytes and cholangiocytes against liver injury and cholestasis. 2
- 158 Gastrointestinal manifestations of inflammatory bowel disease. **2020**,
- 157 Primary Sclerosing Cholangitis. **2020**, 153-159
- 156 Colangitis esclerosante primaria. Una revisi3n narrativa. **2020**, 33, 251-261
- 155 [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis]. **2020**, 75, 246-256
- 154 Review of primary sclerosing cholangitis with increased IgG4 levels. **2020**, 26, 3126-3144 4
- 153 Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis. **2020**, 66, 287-300 1
- 152 Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection. *Journal of Hepatology*, **2021**, 13.4 1
- 151 Autoimmune Overlap Syndromes. **2020**, 137-149
- 150 Bile Acids and Bilirubin in Liver Immunology. **2020**, 103-124
- 149 PSC-AIH Overlap. **2020**, 359-373
- 148 Esclerosis sist3mica y participaci3n gastrointestinal. **2020**, 27, 44-54 0



- 147 Ursodeoksikolik Asit'in Farelerde Pentilentetrazol ile Oluřturulan Akut Epileptik Nöbetler Üzerine Etkisinin Arařılması.
- 146 Autoimmune Hepatitis. **2020**, 419-441
- 145 Primary Biliary Cholangitis: Autoimmune Hepatitis Overlap Syndrome. **2020**, 375-394
- 144 Clinical Genetics of Cholangiopathies. 1-8
- 143 Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus. **2020**, 112, 538-544
- 142 Autoimmunhepatitis (AIH). **2020**, 255-273
- 141 ~~Autoimmunhepatitis~~ **2020**, 114-118
- 140 Diagnostic Liver Immunology. **2020**, 139-150
- 139 Risk Factors. **2020**, 157-169 1
- 138 Sclerosing Cholangitis. **2020**, 392-405
- 137 Cholestatic Diseases, Chronic. **2020**, 497-502
- 136 Hepatotoxicity induced by bodybuilding supplements. **2020**, 66, 28-33
- 135 Colestasis en el adulto: enfoque diagnóstico y terapéutico. Revisión de tema. **2020**, 35, 76-86 0
- 134 Primary Biliary Cirrhosis- Autoimmune Hepatitis Overlap Syndrome. **2020**, 7, 515-517
- 133 Primary biliary cholangitis: review for radiologists. **2021**, 1 1
- 132 Non-tumoral Pathology of the Intrahepatic Biliary Tract. **2021**, 337-364
- 131 Drug-induced liver injuries in practice of primary care physician (review of clinical recommendations). **2020**, 58-69 1
- 130 What is the real function of the liver 'function' tests?. **2012**, 81, 30-6 47

129	Crohn's disease of the small bowel, complicated by primary biliary cirrhosis, Hashimoto thyroiditis, and Raynaud's phenomenon: favorable response of all disorders to adalimumab treatment. <b>2013</b> , 6, 101-5	6
128	Hepatic osteodystrophy. <b>2014</b> , 11, 185-91	24
127	A Review of Inflammatory Bowel Disease in the Setting of Liver Transplantation. <b>2014</b> , 10, 626-30	2
126	Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment. <b>2018</b> , 14, 293-304	6
125	Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance. <b>2018</b> , 14, 427-432	4
124	A Practical Review of Primary Biliary Cholangitis for the Gastroenterologist. <b>2019</b> , 15, 145-154	8
123	Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. <b>2019</b> , 25, 610-624	18
122	Cholangioscopy and its Role in Primary Sclerosing Cholangitis. <b>2020</b> , 8, 42-53	6
121	Treatment of intractable pruritus in patients with cholestasis with molecular adsorbents recirculating system dialysis: a case series. <b>2021</b> , 16, 254-256	
120	Intrahepatic cholestasis of pregnancy: dilemma in diagnosis and management. <b>2021</b> , 1-7	0
119	Liver pathology in pregnancy. <b>2021</b> , 72, 1	0
118	Abordaje del paciente con colestasis y síndrome icterico. Posicionamiento científico conjunto AMH, AMG, AMEG. <b>2021</b> , 87, 80-80	
117	Risk of Hepatobiliary-Gastrointestinal Malignancies and Appropriate Cancer Surveillance in Patients With Primary Sclerosing Cholangitis.. <b>2021</b> , 13, e19922	0
116	Approach to the patient with cholestasis and jaundice syndrome. Joint AMH, AMG, and AMEG scientific position statement. <b>2021</b> , 87, 80-80	
115	Emerging drugs for the treatment of primary sclerosing cholangitis. <b>2021</b> , 62, 23-35	1
114	Cholestasis: algorithms for diagnosis and treatment. <b>2022</b> , 2, 28-36	
113	An Insight into Cholangiocarcinoma and Recent Advances in its Treatment.. <b>2022</b> , 1	1
112	Efficacy of Treatments for Cholestatic Pruritus: A Systemic Review and Meta-analysis.	0

111	A novel serum metabolomic panel distinguishes IgG4-related sclerosing cholangitis from primary sclerosing cholangitis.. <b>2022,</b>	0
110	Haut. <b>2022,</b> 961-996	
109	Cholestatic Liver Disease and Pregnancy: A Systematic Review and Meta-Analysis.. <b>2022,</b> 11,	
108	Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.. <b>2022,</b>	2
107	Pruritus in Pregnancy.. <b>2022,</b> 23, 231	0
106	. <b>2022,</b> 29, 76-79	1
105	Diagnostic and Clinical Value of Specific Autoantibodies against Kelch-like 12 Peptide and Nuclear Envelope Proteins in Patients with Primary Biliary Cholangitis.. <b>2022,</b> 10,	1
104	Managing hepatic complications of pregnancy: practical strategies for clinicians.. <b>2022,</b> 9,	0
103	Da-Chai-Hu-Tang Protects From Acute Intrahepatic Cholestasis by Inhibiting Hepatic Inflammation and Bile Accumulation Activation of PPAR $\alpha$ <b>2022,</b> 13, 847483	0
102	Pregnancy-Associated Liver Diseases.. <b>2022,</b>	2
101	Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy.. <b>2022,</b> 1	0
100	Pruritus: A Sensory Symptom Generated in Cutaneous Immuno-Neuronal Crosstalk.. <b>2022,</b> 13, 745658	0
99	Cholestatic pruritus: a knowledge update.. <b>2022,</b>	
98	Solid extraintestinal malignancies in patients with inflammatory bowel disease.. <b>2021,</b> 13, 1956-1980	0
97	Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.. <b>2021,</b> 13, 1828-1849	1
96	Symptom patterns in the daily life of PSC patients.. <b>2022,</b>	0
95	Table_1.DOCX. <b>2018,</b>	
94	Table_1.XLSX. <b>2018,</b>	

- 93 Treatment of intractable pruritus in patients with cholestasis with molecular adsorbents recirculating system dialysis: a case series. **2021**, 16, 254-256 0
- 92 Gastrointestinal and Nutritional Disorders. **2022**, 7215-7245
- 91 Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. **2022**, 45, 83-90
- 90 Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis.. **2022**, 13, 885229 1
- 89 Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.. **2022**, 11, 0
- 88 Prevalence of Primary Biliary Cholangitis in a Cohort of Primary Sjögren's Syndrome Patients. **2022**,
- 87 Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome. **2022**, 28, 2021-2033 0
- 86 Impact on follow-up strategies in patients with primary sclerosing cholangitis.. **2022**, 0
- 85 The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts.. **2022**, 1 2
- 84 Vitamine D et foie. **2015**, N° 1, 10-18
- 83 Chronic Liver Disease. **2022**, 209-227
- 82 Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome. **2022**, 26, 0
- 81 Indications for Liver Transplantation in Adults: Selection of Patients with End Stage Liver Diseases. **2022**, 451-459
- 80 Rare variant contribution to cholestatic liver disease in a South Asian population in the United Kingdom.
- 79 Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study.
- 78 Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. **2022**, 12, 925 0
- 77 Autoimmune Hepatitis and Overlap Syndrome. **2022**, 149-175
- 76 Acute coronary syndrome after liver transplantation in a young primary biliary cholangitis recipient with dyslipidemia: a case report. **2022**, 8,

75	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	4
74	Prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis: A systematic review and meta-analysis.		0
73	Post-COVID-19 Cholestasis: A Case Series and Review of Literature. <b>2022</b> ,		0
72	Hepatologische Erkrankungen in der Schwangerschaft. <b>2022</b> , 18, 115-133		
71	Management of Incidentally Detected Gallbladder Polyps: Society of Radiologists in Ultrasound Consensus Conference Recommendations.		2
70	Network Proximity-Based Drug Repurposing Strategy for Early and Late Stages of Primary Biliary Cholangitis. <b>2022</b> , 10, 1694		1
69	Odevixibat in progressive familial intrahepatic cholestasis: a profile of its use.		
68	A Review on Biomarkers for the Evaluation of Autoimmune Cholestatic Liver Diseases and Their Overlap Syndromes. 2,		0
67	Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial. <b>2022</b> , 10,		
66	Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. <b>2022</b> ,		2
65	Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.		1
64	Role of ductular reaction and ductular-canalicular junctions in identifying severe primary biliary cholangitis. <b>2022</b> , 100556		0
63	Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis. 13,		0
62	Imaging features of COVID-19-associated secondary sclerosing cholangitis on magnetic resonance cholangiopancreatography: a retrospective analysis. <b>2022</b> , 13,		0
61	Metabolomics-based researches in autoimmune liver disease: A mini-review.		0
60	Prediction and Evaluation of High-risk Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid Therapy: An Early Criterion.		
59	Current epidemiology of cholangiocarcinoma in western countries. <b>2022</b> ,		0
58	Noninvasive diagnosis of AIH/PBC overlap syndrome based on prediction models. <b>2022</b> , 17, 1550-1558		0

57	Ursodeoxycholic Acid in Liver Cirrhosis: A Chinese Perspective. <b>2022</b> , 81-111	0
56	Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. <b>2022</b> , 26,	1
55	Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases. <b>2022</b> , 39, 5126-5143	0
54	Bile duct colonization with <i>Enterococcus</i> sp. associates with disease progression in Primary Sclerosing Cholangitis. <b>2022</b> ,	3
53	Quantitative magnetic resonance cholangiopancreatography metrics are associated with disease severity and outcomes in patients with primary sclerosing cholangitis. <b>2022</b> , 100577	0
52	Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.	0
51	Development of a prognostic MRCP score (DiStrict) for patients with large-duct primary sclerosing cholangitis. <b>2022</b> , 100595	0
50	Confidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey.	0
49	Increased concentrations of conjugated bile acids are associated with osteoporosis in PSC patients. <b>2022</b> , 12,	0
48	MAIT cells ameliorate liver fibrosis by enhancing the cytotoxicity of NK cells in cholestatic murine models.	0
47	Autoimmune Lebererkrankungen <a href="#">Lein Update (Teil 2)</a> . <b>2022</b> , 18, 245-260	0
46	Triptolide increases resistance to bile duct ligation-induced liver injury and fibrosis in mice by inhibiting RELB. 9,	0
45	Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.	0
44	Protocols of Investigation of Neonatal Cholestasis <a href="#">A Critical Appraisal</a> . <b>2022</b> , 10, 2012	0
43	A prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis.	0
42	Mechanisms of pruritus in cholestasis: understanding and treating the itch.	1
41	Gallbladder cancer. <b>2022</b> , 8,	2
40	Prevalence, risk factors and adverse perinatal outcomes for Chinese women with intrahepatic cholestasis of pregnancy: a large cross-sectional retrospective study. <b>2022</b> , 54, 2966-2974	0

39	Disease burden in primary sclerosing cholangitis in the Netherlands; a long-term follow-up study.	0
38	Evaluation and Management of Pruritus in Primary Biliary Cholangitis. <b>2022</b> , 26, 727-745	0
37	Advances in understanding the regulatory mechanism of organic solute transporter $\text{H}^+$ <b>2022</b> , 310, 121109	0
36	Glycocholic acid aggravates liver fibrosis by promoting the up-regulation of connective tissue growth factor in hepatocytes. <b>2023</b> , 101, 110508	0
35	Ursodeoxycholic acid use in lactating female patients is associated with clinically negligible concentrations of this bile acid in breast milk. <b>2022</b> , 12,	0
34	A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis. <b>2022</b> ,	0
33	Approach to the liver biopsy diagnosis of adult cholangiopathies. <b>2022</b> ,	0
32	A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients. <b>2022</b> , 17,	1
31	Spectrum of autoimmune liver disease and real-world treatment experience from a tertiary care hospital. <b>2022</b> ,	0
30	Current trends and future perspectives in the treatment of PBC and PSC: A review. <b>2022</b> , 100065	0
29	Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. <b>2022</b> ,	0
28	Overlap Syndrome with Autoimmune Hepatitis and Primary Sclerosing Cholangitis. 95-104	2
27	Primary Sclerosing Cholangitis: A Clinical Update. 101-110	0
26	Role of Endoscopic Retrograde Cholangiopancreatography in Benign Biliary Diseases.	0
25	Primary sclerosing cholangitis $\Delta$ long night's journey into day. <b>2022</b> , 20, 21-32	1
24	Case series of progressive familial intrahepatic cholestasis type 3: Characterization of variants in ABCB4 in China. 9,	0
23	Enzymes of Fibrosis in Chronic Liver Disease. <b>2022</b> , 10, 3179	0
22	Protective potential of the gallbladder in primary sclerosing cholangitis. <b>2022</b> , 100649	0

- 21 A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. ○
- 20 Automated Image Analysis of Keratin 7 Staining Can Predict Disease Outcome in Primary Sclerosing Cholangitis. ○
- 19 Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis. **2023**, 24, 1559 ○
- 18 Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis. ○
- 17 Environmental Chemicals and Endogenous Metabolites in Bile of USA and Norway Patients with Primary Sclerosing Cholangitis. ○
- 16 An Assessment of the Serum Activity of ADH and ALDH in Patients with Primary Biliary Cholangitis. **2023**, 71, ○
- 15 Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence. **2023**, 12, 213 ○
- 14 Cirrhosis: Reviewing the Literature and Future Perspectives. 111-117 ○
- 13 Non-Neoplastic Disorders of the Liver. **2024**, 489-556 ○
- 12 Health-related quality of life in patients with primary sclerosing cholangitis: A longitudinal population-based cohort study. ○
- 11 Epidemiology of Autoimmune Liver Disease. **2023**, 81, 59-65 ○
- 10 Liver Disease in Pediatric Inflammatory Bowel Disease. **2023**, 129-149 ○
- 9 Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. **2023**, 15, ○
- 8 Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. **2023**, 5, 100719 ○
- 7 Factores asociados a la presencia de pólipos vesiculares verdaderos en pacientes con lesiones polipoides. **2022**, 44, 161-168 ○
- 6 LC-MS/MS: A sensitive and selective analytical technique to detect COVID-19 protein biomarkers in the early disease stage. 1-14 ○
- 5 PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. **2023**, 23, ○
- 4 Management of Clinically Significant Itch in Cholestatic Liver Disease. ○



- 3 Bile Duct Diseases. **2024**, 556-643 ○
- 2 Challenges in pediatric inherited/metabolic liver disease: Focus on the disease spectrum, diagnosis and management of relatively common disorders. 29, 2114-2126 ○
- 1 Interim results from an ongoing, open-label, single-arm trial of odeixibat in progressive familial intrahepatic cholestasis. **2023**, 100782 ○